×Close

Mr. Deven Patel – President, CEO and Co-founder

Mr. Deven Patel is the President, CEO and Cofounder of GIOSTAR. He has also served as the CEO, President and Board of Directors in highly comprehensive environment of Healthcare Management, Architectural, General Construction, Alternative Energy and multifaceted Internet industries. Apart from serving as CEO and President, Mr. Patel has also served in a key positions of several public and private organizations such as Asian & Pacific American Coalition, Asian Outreach Committee – Children Memorial Hospital San Diego, Federation of India Associations, National Federation of Indian American Association, CRY America, Global Organization of People of Indian Origin, Kelly Dean Citizens Awareness Circle, Phillip Redmond Foundation, Lockport Planning Commission.

During his early career, Mr. Patel was involved with the design and construction of several healthcare projects as an architect and a builder. He has also served as a partner for an assisted living and wellness center fostering care for senior citizens suffering from special conditions.

×Close

Dr. Anand Srivastava, M.S., Ph.D. – Chairman, Cofounder and Chief Scientific Officer

Dr. Anand Srivastava has been associated with leading universities and research institutions of USA. In affiliation with University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), USA has developed several research collaborations and has an extensive research experience in the field of Embryonic Stem cell which is documented by several publications in revered scientific journals.

Dr. Anand Srivastava's success has its root in his unique background of expertise in Stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy and clinical research. There are many scientists who can work in a narrowly defined field but few have broad and multidisciplinary experience to carry out clinical research in a field as challenging as Stem cell biology, cancer and gene therapy field. Dr. Anand Srivastava's wide-spectrum expertise is rare in clinical research and perfectly crafted to fit ideally with the GIOSTAR projects for Stem cell transplant, cancer and gene therapy research.

Dr. Anand Srivastava's research work has been presented in various national and international scientific meetings and conferences in India, Japan, Germany and USA. His research articles have been published in peer reviewed medical scientific journals and he has been cited extensively by other scientists. Dr. Anand Srivastava's expertise and scientific achievements were recognized by many scientific fellowships and by two consecutive award of highly prestigious and internationally recognized, JISTEC award from Science and Technology Agency, Government of Japan. Also, his research presentation was awarded with the excellent presentation award in the "Meeting of Clinical Chemistry and Medicine, Kyoto, Japan. He has also expertise in genetic engineering research, developmental biology, immunology, making the transgenic animals and his extraordinary expertise of searching and characterizing the new genes are ideal for our ongoing projects of developing the effective treatments for many degenerative diseases, genetic diseases and cancer. Based on his extraordinary scientific achievements his biography has been included in "WHO IS WHO IN AMERICA" data bank two times, first in 2005 and second in 2010.

Dr. Anand Srivastava's Long Profile

Dr. Anand Srivastava has been associated with leading universities and research institutions of USA. In affiliation with University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), USA has developed several research collaborations and has an extensive research experience in the field of Embryonic Stem cell which is documented by several publications in revered scientific journals.

Dr. Srivastava is a Chairman and Cofounder of California based Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California, (U.S.A.). The company was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world such as Parkinson's, Alzheimer's, Autism, Diabetes, Heart Disease, Stroke, Spinal Cord Injuries, Paralysis, Blood Related Diseases, Cancer and Burns. GIOSTAR is a leader in developing most advance stem cell based technology, supported by leading scientists with the pioneering publications in the area of stem cell biology. Company’s primary focus is to discover and develop a cure for human diseases with the state of the art unique stem cell based therapies and products. The Regenerative Medicine provides promise for treatments of diseases previously regarded as incurable.

Giostar is world’s leading Stem cell research company involved with stem cell research work for over a decade. It is headed by Dr Anand Srivastava, who is a world-renowned authority in the field of Stem cell biology, Cancer, Gene therapy. Several governments including USA, India, China, Turkey, Kuwait, Thailand and many others seek his advice and guidance on drafting their strategic & national policy formulations and program directions in the area of stem cell research, development and its regulations. Under his creative leadership a group of esteemed scientists and clinicians have developed and established Stem cell therapy for various types of Autoimmune diseases and blood disorders which are being offered to patients in USA and soon it will be offered on a regular clinical basis to the people around the globe. Giostar is already the official collaborator of Government of Gujarat, India by setting up a state of art stem cell treatment hospital in Surat civil hospital for the less fortunate tribal populace of the southern belt of Gujarat suffering from Sickle Cell Anemia. Several state Governments in India is looking for a collaborative efforts of GIOSTAR and Dr. Anand to develop stem cell transplant program in their respective states.

SUMMARY OF DR. SRIVASTAVA’S WORK:

Dr. Anand Srivastava’s success has its root in his unique background of expertise in Stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy and clinical research. There are many scientists who can work in a narrowly defined field but few have broad and multidisciplinary experience to carry out clinical research in a field as challenging as Stem cell biology, cancer and gene therapy field. Dr. Anand Srivastava’s wide-spectrum expertise is rare in clinical research and perfectly crafted to fit ideally with the GIOSTAR projects for Stem cell transplant, cancer and gene therapy research.

Dr. Anand Srivastava’s research work has been presented in various national and international scientific meetings and conferences in India, Japan, Germany and USA. His research articles have been published in peer reviewed medical scientific journals and he has been cited extensively by other scientists. Dr. Anand Srivastava’s expertise and scientific achievements were recognized by many scientific fellowships and by two consecutive award of highly prestigious and internationally recognized, JISTEC award from Science and Technology Agency, Government of Japan. Also, his research presentation was awarded with the excellent presentation award in the “Meeting of Clinical Chemistry and Medicine, Kyoto, Japan. He has also expertise in genetic engineering research, developmental biology, immunology, making the transgenic animals and his extraordinary expertise of searching and characterizing the new genes are ideal for our ongoing projects of developing the effective treatments for many degenerative diseases, genetic diseases and cancer. Based on his extraordinary scientific achievements his biography has been included in “WHO IS WHO IN AMERICA” data bank two times, first in 2005 and second in 2010.

POSITIONS HELD BY DR. SRIVASTAVA (1997 to Date):

1. Chairman & Cofounder (2008-till date): Global Institute of Stem Cell Therapy and Research, San Diego, CA. USA.
2. Associate Professor: Department of Cellular and Molecular Biology, School of Medicine, University of California Los Angeles (UCLA), CA, USA.
3. Visiting Senior Scientist: Department of Stem Cell Biology, Burnham Research Institute for Medical Science, San Diego, CA, USA.
4. Senior Scientist: Stem Cell Core Facility, The Salk Research Institute, La Jolla, CA, USA.
5. Associate Professor: Department of Stem Cells and Neurology, School of Medicine, University of California Irvine (UCI), Irvine, CA, USA.
6. Assistant Professor: Cancer Center, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA
7. Honorary Visiting Professor: National Research Institute, Nansei, Mie, JAPAN.

SPECIAL STEM ISSUES OF JOURNALS DEVOTED TO DR. SRIVASTAVA

1. Current Topics of Medicinal Chemistry among top five medicinal chemistry journal devoted its special issue of stem cell to Dr. Srivastava in 2010.
2. Stem Cell International devoted its special issue on stem cells to Dr. Srivastava in 2012.

EXPERT SCIENTIFIC REVIEWER FOR LEADING JOURNALS OF MEDICINE:

Dr. Srivastava is the member of the several scientific review committees and reviewing the research grants. He has written several review articles and scientific manuscripts. He is also the reviewer and editor of several scientific journals.

1. Advances in Stem Cells
2. Current pharmaceutical Design
3. Current Topics in Medicinal Chemistry
4. Stem Cells
5. Stem Cell International
6. Current in Cell Medicine
7. Journal of Stem Cell Research and Therapy
8. Conference Papers in Molecular Biology
9. Journal of Pharmaceutics
10. Current Pharmaceutical Biotechnology
11. Open Journal of Organ Transplant Surgery
12. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry‏
13. Stem Cells and Cloning: Advances and Applications
14. Blood and Lymphatic Cancer: Targets and Therapy
15. Degenerative Neurological and Neuromuscular Disease
16. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
17. Immuno Targets and Therapy
18. Current Vascular Pharmacology
19. Gastrointestinal Cancer: Targets and Therapy
20. Journal of Bioengineering and Biomedical Sciences
21. The Application of Clinical Genetics
22. Journal of Tissue Science & Engineering
23. Neuropsychiatric Disease and Treatment
24. Current Tissue Engineering
25. Hepatic Medicine: Evidence and Research
26. Current Drug Discovery Technologies
27. Current Bioactive Compounds
28. Transplant Research and Risk Management
29. Biosimilars
30. Current Drug Delivery
31. Journal of Experimental Pharmacology
32. Open Journal of Regenerative Medicine
33. Current Diabetes Reviews
34. Journal of Fertilization: In Vitro
35. Clinical and Translational Medicine

FELLOWSHIPS/ AWARDS:

2003 Awarded with “NIMA (National Integrated Medical Association) Outstanding Scientist” award from NIMA, India.
2003 Awarded with “Excellent Scientist Award” from Bharat Vikas Parisad, India for continuous excellent performance in the life science research. The 18th International Congress of Clinical Chemistry and Laboratory Medicine Kyoto “Excellent Poster Award”, Kyoto, Japan.
2002 “Best Scientist Award” for excellent contribution in the field of life science research from Kayastha Maha Sabha, Varanasi, India.
1998-2000: “Long-term STA/JISTEC Award” (Science and Technology Agency/Japan International Science and Technology Exchange Center, JAPAN)- Fellowship award for two year from government of Japan.
1997-1998: “Short-term STA/JISTEC Award” (Science and Technology Agency/Japan International Science and Technology Exchange Center, JAPAN)- Fellowship Award for three months from government of Japan (October 1997- January 1998).
1997-1998: Awarded with “Research Associate-ship award” from CSIR (Council of Scientific and Industrial Research) Government of India.
1990-1995: “CAS (Center of Advanced Study) Award” in Zoology. A doctoral research fellowship award from Government of India.

THE FOLLOWING SUMMARIZES DR. SRIVASTAVA’S MAJOR SCIENTIFIC ACHIEVEMENTS:

1. Dr. Srivastava developed the animal material free and serum free Human embryonic Stem cell culture condition to use the Human ES cells to treat the human diseases.
2. Dr. Srivastava for the first time showed that if the ES cell injected into developing fetuses in utero takes participation in development of all body of a living organism.
3. For the first time he showed that ES cell is better accepted by the transplanted animals in comparison to adult stem cells.
4. For the first time he showed the way to generate the high number of pre-erythrocytes using glucocorticoid hormone. Which may be use to treat several blood diseases.
5. For the first time Using ES cells he generated the high number of CD34+ expressing a kind of hematopoietic stem cell which can be used to treat several autoimmune diseases, immune reconstitution and blood diseases.
6. For the first time he showed the molecular mechanism behind the regulation of ES cell differentiation into hematopoietic cells.
7. For the first time he showed that ES cells automatically recognize the damage portion of the brain and can be used to repair the damage brain.
8. For the first time he showed that ES cell can be used to treat the Crohn’s disease a kind of colon cancer.
9. For the first time, he demonstrated that the mammalian fetuses can be programmed inside the mother uterus to face the challenges of the future possible infection. This finding is very important to develop the advanced therapy for any fatal disease such as cancer and AIDS. Utilizing these techniques, fetuses can be given information about all possible infections and the capability to counter those infections and disease.
10. He has demonstrated for the first time that it is easy to correct the genetic diseases in developing fetus in utero in comparison to adult animals.
11. He has shown for the first time that the lung cancer cells can be treated with the help of plant product curcumin and can be used as effective cancer therapeutic agent. He also demonstrated that how curcumin regulated the genes related to programmed death of cancerous cell. Finding help in development of non-toxic, less expensive, easily available drug for cancer.
12. The biggest problem in the treatment of cancer and other diseases is the non-specific distribution of medicine and toxic chemotherapeutic agents to healthy tissues. Dr. Srivastava for the first time developed a technique that can help in targeting the diseased tissues using the tissue receptor binding peptide ligands. These techniques can be used for targeted delivery of drugs and genes (in case of genetic disease) to the specific fetal tissues inside the mother uterus without harming the normal tissues of mother and fetus.
13. For the first time, He demonstrated the insertion of foreign pancreas enzyme specific gene promoter into the developing animals embryo and successfully shown the incorporation and regulation of pancreatic enzyme in the control of inserted gene. This is very important finding and proves that the defective genes can be replaced easily and effectively by the normal functional genes during the development of animals. This finding will help in the change of defective genes of insulin hormone, which is present in the pancreas of diabetic patients and many other genetic diseases also.
14. For the first time, He reported the gene sequence of all important pancreatic enzymes (three isoform of trypsinogen, two isoforms of chymotrypsinogen, four types of elastases, three forms of carboxypeptidases and lipase) and its evolutionary relationship with human. Also,he reported first time the regulation of digestion by these enzymes in the alimentary canal during digestion of proteins in the developing animals.
15. For the first time, He cloned and sequenced two types of human homologue of Vitamin D receptor gene from Japanese flounder, which is most important receptor, which help in the development of bone. Before my report, characters of this gene were not known in Japanese flounder. This finding helped in the understanding of the genetic evolution of mammals.
16. For the first time, he cloned and sequenced the homologue of human placental protein, PP11, and mouse T cell specific, Tcl-30, in pancreas of Japanese flounder, this study suggest that these genes evolved from the fish pancreas and in fish it helps in synthesizing the digestive enzymes but during the evolution its function got changed and work differently in the mammalian placenta. This was very important finding related to this rare gene.
17. For the first time, He has shown that the Hox and sonic hedgehog genes regulate the development of bones and respiratory organs. He also demonstrated that how these genes could be regulated artificially. This was very important finding because it gives the idea that how genes regulate the development of organs.
18. For the first time, He has purified and characterized the human homolog of AAT and ASPT enzymes, which is the basic clinical marker in all the infection and major marker of liver function test.
19. For the first time, he demonstrated the co-ordination of AAT and ASPT enzymes in the production of energy through the amino acids after aerobic respiration.
20. For the first time, he has shown that according to metabolic demand of the body AAT and ASPT genes synthesized additional forms of its isoform to cope up with the extra energy demand and work as an “on” and off” switch.

DR. SRIVASTAVA’S EXCELLENCE IN SEVERAL ADVANCED BIOLOGICAL TECHNIQUES:

Techniques related to Human Embryonic Stem Cell Human Embryonic Stem cell culture, Serum free and feeder free hES cell culture, in vitro differentiation of hES cells into neural cells, in vitro differentiation of hES into hematopoietic cells and red blood cells under the control of cytokines. Gene regulation studies using RT-PCR, Real time PCR, Northern blot, Southern blot and in situ hybridization, immunohistochemistry during the differentiation, Cell cycle regulation studies during differentiation of hES cells into hematopoietic and neural cells. Use of siRNA for blocking a specific cell cycle. FACS analysis of differentiated cells and cell shorting. ES cell transfection.

In vivo studies with ES cells Created a mouse model for study the effect of ES cells on damaged brain. Injection of ES cells into mouse brain, tail vein injection, in vivo tracking of ES cell migration. Used the ES cells for repair of damaged brain. Gene and protein regulation during neural cell differentiation. Studies on transcription factors. Histochemical analysis of transplanted ES cells using fluorescent, confocal microscopy and deconvolution microscopy. Created a mouse model for Crohn’s disease. In vivo migration of ES cells into diseased portion of intestine. Studies on inflammatory cytokines during the repair of Crohn’s disease with ES cell. Gene regulation studies during this process. Elisa assays for the cytokines. Stem cell niche interaction.

Created in utero mouse model for ES cells transplantation. Used this model to make chimeric animals. Distribution and differentiation of ES cells into developing mouse embryo. FACS and magnetic shorting of ES cells derived CD31+, CD34+, CD45+ cells from the transplanted animal tissues. Gene and protein regulation of in vivo differentiating cells.

Created immunocompromised mouse model to study the effect of in vivo immune component on T7 phage virus. In vivo selection of tissue specific receptor binding peptide using in vivo biopanning method. Tissue targeted gene delivery to correct the blood related genetic diseases. Gene cloning, gene sequencing, synthesis of RNA probes.
Protein and enzyme biochemistry
Protein assay, peptide structure and amino acid sequencing, Enzyme assay, Ultra centrifugation, Ion exchange chromatography, column chromatography, HPLC, Protein and gene regulation during the development. Enzyme kinetics, Enzyme inhibition, SDS gel electrophoresis, Protein characterization.

Selection of cell receptor binding peptide and Phage display technology

- Selection of tissue receptor binding peptides using T7 phage display system.
- In vivo and in vitro biopanning for selection of receptor binding peptides sequences.
- Characterization of targeted cells and tissues using histochemistry and gene expression analyses.
- In vivo delivery of drugs and genes to targeted tissues using microinjection.

Cancer Research

- Studying the role of pharmaceutical agent curcumin as an anti-lung cancer drug and develop it as a non-toxic cancer drug.
- Role of apoptotic genes on the lung cancer cell lines.
- Development of tissue targeted delivery protocol of pharmaceuticals agents for cancer and genetic diseases

Fluorescence techniques for nucleic acid sequence detection: Clinical and diagnostic applications

- Fluorescent labeling of DNA and RNA probes.
- Fluorescence resonance energy transfer (FRET) protocols for DNA and RNA sequence. detection in real time (Sequence Detection System 7700, ABI, Perkin Elmer)
- FRET protocols for monitoring ribozyme reactions and kinetics in real time (TaqMan, SDS 7700, ABI, Perkin Elmer).
- Accessibility studies for DNA and RNA target sequences using FRET.
- Fluorescence polarization protocols for monitoring ribozyme reactions (POLARstar, BMG, GmbH) and for DNA and RNA sequence detection.
- Sequence detection with Syber green dye in real time quantitative PCR by Light Cycler (Roche Diagnostics, USA).
- Single nucleotide polymorphism detection in real time with LightCycler hybridization probes (Roche Diagnostics, USA).

Gene detection technology: Research and Clinical applications

- Preparation of radio labeled & fluorescent labeled RNAs (ribozymes and target substrates).
- In vitro transcription of RNA.
- Expression of ribozymes in yeast.
- Isolation and purification of cellular RNA.
- RNase Protection Assay.
- Kinetic characterization of ribozymes & binding kinetics using fluorescence methods.
- Designing, synthesis and characterization of allosteric ribozymes induced by small drug ligands (such as theophylline & caffeine).

In utero transplantation: Clinical Research to cure the fetal genetic diseases

- Developed in utero microinjection techniques to transplant the bone marrow and stem cells to cure blood related genetic disease.
- Harvest the fetal liver, bone marrow and mouse embryonic stem cells for transplantation.
- Culture mouse embryonic stem cell and in vitro differentiation into the blood cells.
- Fractionation of cells using flow cytometry techniques.

Standard Molecular biology techniques - Standard and site directed mutagenesis polymerase chain reaction (PCR).
- Preparation and purification of plasmids.
- Transformations and Transfection of DNA.
- Cloning of DNA.
- Solid phase synthesis of DNA (Gene Assembler, Pharmacia).
- DNA sequencing & fragment analyses (ABI 310 Gene Sequencer, Perkin Elmer).
- Quantitation of DNA, RNA and proteins.
- Mammalian cell culture and yeast culture.
- Gel electrophoresis (polyacrylamide and agarose).
- Capillary gel electrophoresis (ABI 310 Gene Sequencer, Perkin Elmer).
- Column/ gel/ thin layer chromatography.
- Autoradiography by phosphorimager (Storm, Molecular Dynamics, USA).
- High Performance Liquid Chromatography (HPLC).
- Preparation and purification of chemical reagents & solvents.
- Enzyme/ Protein/ purification and characterization.
- Isolation of Genomic DNA, Genomic library Construction.
- Radioimmunoassay.

General molecular and biochemical techniques

mRNA preparation and purification, Primer designing, Real-time PCR, RT-PCR, DNA cloning, DNA sequencing, Isolation of Genomic DNA, Genomic library Construction, Transformation, Transfection, Cell culture, Plasmid purification, RNA probe making, Different kinds of microscopy, In situ hybridization, Southern blotting, Northern blotting, Western blotting, Spectrophotometery, In utero-microinjection, Column chromatography, HPLC, PAGE, Agarose gel-electrophoresis, Enzyme assay, Protein assay, Enzyme/ Protein/ DNA purification, Histology, Phage display for tissue targeting, Radio-immunoassay,

INVITED SPEAKER AND PRESENTATIONS OF DR. SRIVASTAVA’S SCIENTIFIC FINDINGS IN NATIONAL AND INTERNATIONAL CONFERENCES:

1. Srivastava A.S. Invited Speaker, STEM 2013, 9 Th Annual Conference on Biotechnology - Focusing On Latest Trend in Stem Cells, Regenerative Medicine and Tissue Engineering Mumbai, India, January 2013.

2. Srivastava A.S. "International Conference on Regenerative and Functional Medicine" (Regenerative Medicine-2012), San Antonio, USA. November 2012.

3. Sriavstava A.S. 2nd International Congress on Neurology & Epidemiology; "Impact of drugs on the natural history of neurological diseases". Nice, France. November 2012.

4. Srivastava A.S. Invited Speaker, International Expo and Conference on Analytrix & HPLC, Chicago, USA. October 2012.

5. Srivastava A.S. Invited Speaker at "International Conference on Emerging Cell Therapies" (Cell Therapy-2012) Chicago, USA. October 2012.

6. Srivastava A.S. Invited Speaker, 6th Neurodegenerative Conditions Research and Development Conference San Francisco, CA, USA. September 2012.

7. Srivastava A.S. 8th International Congress on Mental Dysfunction & Other Non-Motor Features In Parkinson's Disease and Related Disorders, Berlin, Germany. May 2012.

8. Srivastava A.S. International Conference and Exhibition on Neurology & Therapeutics Las Vegas, USA. May 2012.

9. Srivastava A.S. Montreal International Biotechnology Forum, Montreal, Quebec, Canada. May 2012.

10. Srivastava A.S. Invited Speaker, International Association of Neurorestoratology (IANR) V and 9th Global College Neuroprotection and Neuroregeneration (GCNN) conference with the 4th International Spinal Cord Injury Treatment & Trial Symposium (ISCITT) Xi’an City, China. May 2012.

11. Srivastava A.S. International Forum on the Mediterranean Diet, Ravello - Amalfi Coast, Italy. March 2012

12. Srivastava A.S. Hong Kong international Stem Cell Forum 2012, Hong Kong. February 2012.

13. Srivastava A.S. 4th International Conference on Drug Discovery and Therapy" (4th ICDDT 2012) Dubai, UAE, February 2012.

14. Srivastava A.S. Evolving Strategies in Hematopoietic Stem Cell Transplantation- San Diego, USA. February 2012.

15. Srivastava A.S. Hebei International Biotechnology Forum; Shijiazhuang, Hebei, China. November 2011

16. Srivastava A.S. 3rd International Conference on Drug Discovery and Therapy. Regenerative Medicine. Dubai, UAE. February 2011.

17. Srivastava A.S. 3rd Annual Congress of Regenerative Medicine & Stem Cell-2010, Shanghai, China. December 2010.

18. Srivastava A.S. 1st Annual Tetra-Congress of MolMed-Personal Medicine Congress 2010, Shanghai, China. November 2010.

19. Srivastava A.S. International Association of Neurorestoratology(IANR), American Journal of Neuroprotection and Neuroregeneration, Beijing, China. October 2010.

20. Srivastava A.S. EPS Global International Neuroscience Forum. Nha Trang, Vietnam. October 2010.

21. Srivastava A.S. EPS Global International Neuroscience Forum, Guangzhou, China. September 2010.

22. Srivastava A.S. 4th Academic Congress of International Chinese Neurosurgical Sciences. Chengdu, China. June 2010.

23. Srivastava A.S. 1st Annual World Congress of Immunodiseases and Therapy (WCIT 2010). Beijing, China. May 2010.

24. Srivastava A.S. 3rd PepCon-2010 - Protein Misfolding and Neurodegeneration. Beijing, China. March 2010

25. Srivastava A.S. Potential use of ES cells in hematopoietic and neural diseases. City of Hope National Medical Center, Duarte, California, USA. January, 2009.

26. Srivastava A.S. Differentiation of Human Embryonic Stem cell into erythrocyte and neural precursor cells: Its potential application. Cleveland Clinic, Cleveland, Ohio, USA, December, 2008.

27. Srivastava A.S. Potential of ES cell in repair of Hematopoietic and neural diseases. International Conference in Stem cell, Kerala, India, August, 2008.

28. Srivastava A. S., Singh U. and Carrier E. Embryonic stem cell improve colitis and decrease IL- 12 levels in the colitis mice. BMRP Fourth Annual Investigator Meeting, Los Angeles, USA. 2006

29. Carrier E., Shermila Kausal and Srivastava A. S. Gene Regulation During the Erythrocytic Differentiation of Embryonic Stem Cells. Blood (ASH Meeting), 2005.

30. Carrier E., Shermila Kausal and Srivastava A. S. Differentiation of Human ES cell into the Hemangioblast. Blood (AHS Meeting), 2005.

31. Srivastava A.S., Zhongling F., Victor A., Kim H.S. and Carrier E. Repair of Crohn’s disease with embryonic stem cells. Broad Medical Research Program, Third Annual Investigator Meeting, Los Angeles, CA, USA, 2005.

32. Srivastava A.S., Shenouda S. and Carrier E. Damaged murine brain induces ES cells into migration and proliferation. Blood:104, 779a, 2004.

33. Srivastava A.S., Shenouda S. and Carrier E. Increased expression of OCT4,SOX2 and FGF4 genes following injection of embryonic stem cell into damaged murine brain. American Society of Gene Therapy, 2004.

34. Srivastava A.S. and Carrier E.; Distribution and stability of T7 phage in mouse blood and tissues. Molecular Therapy:7, 230, 2003.

35. Moustafa M., Srivastava A.S., Nedelcu E., Minev B., Carrier E.; Chimerism and tolerance post in utero transplantation with ontogenically different sources of stem cells. 32nd annual meeting of the international society for Experimental Hematology, 31, 274, 2003 (Paris, France).

36. Steve S., Srivastava A.S. Carrier E.; In vivo survival of hematopoietic stem cell in mouse brain.11th international symposium on recent advances in Stem cell transplantation, 89-90, 2003 (San Diego, USA).

37. Srivastava A.S., Carrier E.; Distribution and stability of T7 phage in mouse. 11th international symposium on recent advances in Stem cell transplantation, 93, 2003 (San Diego, USA).

38. Elena N., Srivastava A.S., Varki N.M., Assatourian G. and E. Carrier; Embryonic stem cells survive and proliferate after intraperitoneal In utero transplantation and produce teratocarcinomas. Blood:160b, 2002.

39. Srivastava A.S and E. Carrier; In utero targeting the fetal liver by using T7 phage display system. Blood:489b, 2002.

40. Srivastava A.S. and E. Carrier; Factor responsible for in vivo neutralization of T7 phage display vector in the blood of mice. Blood:489b, 2002.

41. Srivastava A.S. and E. Carrier; Distribution and stability of T7 phage in the mouse after intravenous administration. ICCC, Kyoto, Japan. (October 2002).

42. Srivastava A.S., T. Kaido and E. Carrier; Immunological factors that affect the in vivo fate of T7 phage in the mouse. Molecular Therapy:5, 713, 2002.

43. Srivastava A.S., E. Nedelcu and E. Carrier; Engraftment of murine embryonic stem cells after in utero transplantation. Molecular Therapy:5, 1132, 2003.

44. M. Rizzi, T. Kaido, M.Gerloni, K.Schuler, A. S. Srivastava, E.Carrier and M. Zanetti; Neonatal T cell immunity by in utero immunization. AAI 2002 annual meeting, April 20 - 24, New Orleans, Experimental Biology 2002 sponsored by 7 FASEB societies.

45. Srivastava A.S., T. Kaido and E. Carrier; Kinetics of T7 phage neutralization in the blood of normal and immunodeficient mice. Blood:407, 2001.

46. Hassan S., Jody D., Srivastava A.S., T.H. Lee, M.P. Busch, Carrier E.; Immunity without microchimerism after in utero transplantation of Hematopoietic stem cell. Blood:320, 2001.

47. Srivastava A.S., Felix Tinkov, T. Friedmann and E. Carrier; Detection of T7 phage in the fetus after Systemic administration to pregnant mice. Molecular Therapy:4, 760, 2001.

48. Pillai G.R., Srivastava A.S., Hassan S., Carrier E. Differential sensitivity of human lung cancer cell lines to curcumin. 9th Annual International Symposium on Recent Advances in Hematopoietic Stem cell Transplantation. USA. 2001.

49. Hassan S., Jody D., Srivastava A.S., Carrier E.; The role of I-E molecule on survival rate and tolerance after in utero transplantation. The 42 ASH meeting, San Francisco, USA. 2000.

50. Suzuki T., Srivastava A.S., Kurokawa T.; Identification of cDNA encoding two subtypes of vitamin D receptor in flounder, Paralichthys olivaceus. Meeting of the Japanese Society of Fisheries Science, April 2 - 4, 2000, Tokyo, JAPAN.

51. Srivastava A.S., Suzuki T., Kurokawa T., Kamimoto M., Nakatsuji T.; GFP expression in pancreas of developing fish embryo under control of Carboxypeptidase A promoter. Plant and Animal Genome-VIII (PAG-VIII), Conference, San Diego, California, USA. January 9th to 12th, 2000.

52. Srivastava A.S., Suzuki T., Kurokawa T.; Molecular cloning of serine protease cDNAs from pancreas of Japanese flounder, Paralichthys olivaceus. Meeting of the Japanese Society of Fisheries Science, Tokyo, JAPAN. 1999.

53. Suzuki T., Srivastava A.S., Kurokawa T.; Cloning of FGFRs from Flounder embryos, and their expression during axial skeletal development. 32nd Annual Meeting of the Japanese Society of Developmental Biologists. JAPAN. 1999.

54. Suzuki T., Srivastava A.S., Kurokawa T.; Expression of Signal molecules during axial skeleton development in Japanese flounder. Meeting of the Japanese Society of Zoological Science. JAPAN. 1999.

55. Suzuki N., Suzuki T., Srivastava A.S., Kurokawa T.; cDNA cloning and expression analysis of receptor for calcitonin and calcitonin related peptide from Japanese flounder. Meeting of the Japanese Society of Zoological Science. JAPAN. 1999.

56. Srivastava A.S., Trigun S.K., Singh S.N.; Purification and kinetics of cytosolic aspartate aminotransferase from liver of air-breathing and non air-breathing fish. National Symposium on Comparative Physiology & Endocrinology, Raipur, INDIA. 1997.

57. Srivastava A.S., Trigun S.K., Singh S.N.; Cytosolic alanin aminotransferase from air-breathing and non air- breathing fish. Proceedings of the Symposium on Frontier Topics in Biochemistry and Molecular Biology, Banaras Hindu University, Varanasi, INDIA. 1996.

58. Srivastava A.S., Trigun S.K., Singh S.N.; Studies on aspartate aminotransferase during reproductive cycle of C. batrachus and L. rohita. Proceeding of the 65th Annual Meeting of the Society of Biological Chemists, I.I.Sc., Banglore, INDIA. 1996.

59. Srivastava A.S., Singh S.N.; A comparison of cytosolic and mitochondrial aminotransferases in fishes. Proceedings of the 4th Convention of Indian Society of Agricultural Biochemist, Banaras Hindu University, Varanasi, INDIA. 1995.

SCIENTIFIC PUBLICATIONS:

1. Embryonic Stem Cells in Medicinal Chemistry and Drug Development. Srivastava AS. Curr Top Med Chem. 2011 Mar 30.

2. Artificial Hematopoietic Stem Cell Niche: Bioscaffolds to Microfluidics to Mathematical Simulations. Didwania M, Didwania A, Mehta G, Basak GW, Yasukawa S, Takayama S, de Necochea-Campion R, Srivastava A, Carrier E. Curr Top Med Chem. 2011 Mar 30.

3. Cancer Stem Cells and Colorectal Cancer: An Overview.
Dhawan P, Ahmad R, Srivastava AS, Singh AB. Curr Top Med Chem. 2011 Mar 30.

4. Mitochondrial function controls proliferation and early differentiation potential of embryonic stem cells. Mandal S, Lindgren AG, Srivastava AS, Clark AT, Banerjee U. Stem Cells. 2011 Mar;29(3):486- 95.

5. Grzegorz Wladyslaw Basak, Srivastava AS, Rakesh Malhotra, Ewa Carrier. Multiple Myeloma Bone Marrow Niche. Curren. Pharm. Biotech, 2009.

6. Srivastava AS, Malhotra R, Jason Sharp and Berggren T. Potentials of ES Cell therapy in Neurodegenerative Diseases. Curren. Pharm. Design, 14:3873-9.2008.

7. Anand S. Srivastava, Rangnath Mishra, Sharmeela Kausal, Dharam P. Chauhan and Ewa Carrier; Clinical Prospects of Embryonic Stem Cells in treatment of Hematopoietic Disorders. Curren. Pharm. Biotech. 8: 51-56, 2007.

8. Anand S. Srivastava, Elena Nedelcu, Babak Esmaeli-Azad, Rangnath Mishra and Ewa Carrier; Thrombopoietin Enhances Generation of CD 34+ Cells from Human Embryonic Stem Cells. Stem Cells, 25:1456-61, 2007.

9. Anand S. Srivastava, Dharam Chauhan, Zong Ling Feng, Hyun S Kim and Ewa Carrier; Transplantation of embryonic stem cell in CDIL10-/- KO mouse, an animal model of colitis, antagonizes the manifestation of Crohn’s Disease. BBRC 361:953-959, 2007.

10. Anand S. Srivastava, Steve Shenouda, Rangnath Mishra and Ewa Carrier; Transplanted Embryonic Stem cells Successfully Survive and Proliferate in Brain and Migrate to Damaged Regions of the Brain. StemCells, 24:1689-94, 2006.

11. Anand S. Srivastava, Sharmeela Kaushal, Rangnath Mishra, Thomas A. Lane and Ewa Carrier; Dexamethasone facilitates erythropoiesis in murine embryonic stem cell differentiating into hematopoeitic cells in vitro. BBRC, 346:508-16, 2006.

12. Marta R., Mara G., Srivastava A.S., Matthew, C. W., Kilian S., Carrier E., and Zanetti M.; Immunity over tolerance targeting fetal liver B cells. Vaccine, 23:4273-82, 2005.

13. Feng Z, Srivastava AS, Mishra R, Carrier E., A regulatory role of Wnt signaling pathway in the hematopoietic differentiation of murine embryonic stem cells. Biochem. Biophys. Res. Commun., 324:1333-9, 2004

14. Srivastava A.S., Chauhan, D.P. and Carrier E.; In utero detection of T7 phage in the fetal tissues after systemic administration to pregnant mice. Biotechniques, 37:81-83, 2004.

15. Srivastava A.S., Kaido T., Carrier E.; Immunological factors that affect the in vivo fate of T7 phage in the mouse. J of Virol. Meth., 115:99-104, 2004.

16. Srivastava A.S, G. Radhakrishna Pillai, Dharam P. Chauhan and Ewa Carrier; Induction of apoptosis in human lung cancer cells by dietary Curcumin. Cancer letters, 208:163-170, 2004.

17. M. E. Moustafa, A. S. Srivastava, E. Nedelcu, S. Shenouda and E. Carrier; Chimerism and tolerance post in utero transplantation with ontogenically different sources of stem cells. Transplantation, 78:1274-1282, 2004.

18. A. S. Srivastava, M. E. Moustafa, S. Shenouda, D. P. Chauhan and E. Carrier; In utero gene therapy: prospect and future. Curren. Pharm. Des., 10:3663-72, 2004.

19. Anand S. Srivastava, Ichiro Oohara, Tohru Suzuki, Steve Shenouda, Surender N. Singh, Dharam P. Chauhan and Ewa Carrier; Purification and properties of cytosolic alanine aminotransferase from the liver of two fresh-water fish species, Clarias batrachus and Labeo rohita. Comp. Biochem. Physiol-B, 137:197-207, 2004.

20. Suzuki,T., Srivastava,A.S. and Kurokawa,T., Paralichthys olivaceus COL1A1 mRNA for type 1 collagen alpha 1, complete cds. Nat. Cent. Biotech. Infor., USA, AB196513, 2004.

21. Suzuki,T., Srivastava,A.S. and Kurokawa,T., Paralichthys olivaceus COL1A2 mRNA for type 1 collagen alpha 2, complete cds. Nat. Cent. Biotech. Infor., USA, AB196514, 2004.

22. Suzuki,T., Srivastava,A.S. and Kurokawa,T., Paralichthys olivaceus COL1A3 mRNA for type 1 collagen alpha 3, partial cds. Nat. Cent. Biotech. Infor., USA, AB196515, 2004.

23. Suzuki,T., Srivastava, A.S. and Kurokawa,T., Paralichthys olivaceus COL1A1 gene for type 1 collagen alpha 1, promoter region. Nat. Cent. Biotech. Infor., USA, AB196516, 2004.

24. Suzuki,T., Srivastava,A.S. and Kurokawa,T., Paralichthys olivaceus COL1A3 gene for type 1 collagen alpha 3, promoter region. Nat. Cent. Biotech. Infor., USA, AB196517, 2004.

25. Srivastava A.S., Kurokawa T., Suzuki T.; Molecular cloning and cDNA sequence analysis of carboxypeptidases A1, A2 and B from the Japanese flounder Paralichthys olivaceus. Comp. Biochem. Physiol-B, 135:593-599, 2003.

26. Hassan S., Jody D., Gilpin E.A., Srivastava A.S., Carrier E.; Tolerance and immunity following in utero transplantation of allogeneic fetal liver cells: The cytokine shift. Cell Transplantation, 12:75-82, 2003.

27. Tohru Suzuki, Anand S. Srivastava, Tadahide Kurokawa; A homologue of human placental protein, PP11, and mouse T cell-specific, Tcl-30, in exocrine pancreas of a teleost Paralichthys olivaceus. Comp. Biochem. Physiol-B, 133:325-329, 2002.

28. Anand S. Srivastava, Tohru Suzuki, Tadahide Kurokawa; mRNA expression of pancreatic enzyme precursors and estimation of protein digestibility in first feeding larvae of the Japanese flounder, Paralichthys olivaceus. Comp. Biochem. Physiol-A, 132:629-635, 2002. 29. Hassan S., Jody D., Srivastava A.S., Gilpin E., Lee T, Carrier E.; Alloreactivity following in utero transplantation of cytokine-stimulated hematopoietic stem cells: The role of recipient CD4 - cells. Exp. Hematol., 30:617-624, 2002.

30. Tohru Suzuki, Anand S. Srivastava, Tadahide Kurokawa; cDNA Cloning and phylogenetic analysis of pancreatic serine proteases from Japanese flounder, Paralichthys olivaceus. Comp. Biochem. Physiol-B, 131:63-70, 2002.

31. Suzuki, T., Srivastava, A.S. and Kurokawa, T; Paralichthys olivaceus ppsb mRNA for pancreatic protein with two somatomedin B domains. Nat. Cent. Biotech. Infor., USA, AB035673, 2002.

32. Tohru Suzuki, Tadahide Kurokawa, Anand S. Srivastava; Induction of bent cartilaginous skeletons and undulating notochord in flounder embryos by disulfiram and α, ά- Dipyridyl. Zoological Science, 18:345-351, 2001.

33. Tohru Suzuki, Nobuo Suzuki, Anand S. Srivastava, Tadahide Kurokawa; Identification of cDNA encoding two subtypes of vitamin D receptor in flounder, Paralichthys olivaceus. Bichem. Bio. Res. Commu. 270:40-45, 2000.

34. Suzuki,T., Suzuki,N., Srivastava, A.S and Kurokawa,T; Paralichthys olivaceus VDRb mRNA for vitamin D receptor b, complete sequence. Nat. Cent. Biotech. Infor., USA, AB037673, 2000.

35. Suzuki,T., Suzuki,N., Srivastava, A.S and Kurokawa,T;Paralichthys olivaceus VDRb mRNA for vitamin D receptor b, complete sequence. Nat. Cent. Biotech. Infor., USA, AB037674, 2000.

36. Suzuki,T. and Srivastava, A.S; Keratin expressed at esophagus and skin of flounder larvae. Nat. Cent. Biotech. Infor., USA, AB049616, 2000.

37. Suzuki T., Srivastava A.S., Kurokawa T.; Experimental induction of jaw and gill skeletal malformation in Japanese flounder, Paralichthys olivaceus, larvae. Aquaculture, 185: 175-187, 2000.

38. Suzuki T., Srivastava A.S., Kurokawa T.; Hoxb-5 is expressed in gill arch 5 during pharyngeal arch Development of flounder Paralichthys olivaceus embryos. Int.J.Dev.Biol, 43:357-559, (1999).

39. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for trypsinogen 1. Nat. Cent. Biotech. Infor., USA, AB029750, (1999).

40. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for trypsinogen 2. Nat. Cent. Biotech. Infor., USA, AB029751, (1999).

41. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for trypsinogen 3. Nat. Cent. Biotech. Infor., USA, AB029752, (1999).

42. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for chymotrypsinogen 1. Nat. Cent. Biotech. Infor., USA, AB029753 (1999).

43. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for chymotrypsinogen 2. Nat. Cent. Biotech. Infor., USA, AB029754 (1999).

44. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for elastase 1 precursor. Nat. Cent. Biotech. Infor., USA, AB029755, (1999).

45. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for elastase 2 precursor. Nat. Cent. Biotech. Infor., USA, AB029756, (1999).

46. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for elastase 3 precursor. Nat. Cent. Biotech. Infor., AB029757, (1999).

47. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for elastase 4 precursor. Nat. Cent. Biotech. Infor., USA, AB029758, (1999).

48. Srivastava A.S., Oohara I., Suzuki T., Singh S.N.; Activity and expression of aspartate aminotransferase during reproductive cycle of a fresh water fish, Clarias batrachus. Fish Physiol.Biochem., 20:243-250,1999.

49. Srivastava A.S., Oohara I., Suzuki T., Singh S.N.; Activity and expression of Glutamate Oxaloacetate Transaminase during reproductive cycle of a fresh water fish Labeo rohita. Fisheries Science, 64(4):621-626,1998.

50. Srivastava A.S., Trigun S.K., Singh S.N.; Activity of cytosolic and mitochondrial alanin aminotransferase during pre-spawning phase in air-breathing and non air-breathing fishes. J.Sci.Res., 47:33-38,1997.

MEMBERSHIP:

1. American Society of Gene therapy, U.S.A.
2. American Society of Hematology, U.S.A.
3. Internet Community for Biological and Medical Research (BioMedNet), USA.
4. Research Gate, San Diego, California, USA.

×Close

Dr. Ewa Carrier, MD – Medical Director

Dr. Carrier, a Stanford graduate, is a world-renowned clinician and research specialist in stem cells transplantation. She has been trained in the world famous transplant center at the University of California San Francisco, and spend last 15 years working on research and clinical aspects of transplantation. She has developed a unique in utero stem cell transplantation model and was Principal Investigator on prenatal transplantation model in humans. She has also developed unique serum-free culture conditions for culturing human embryonic stem cells and differentiated them into erythrocyte precursors. She actively participates in national clinical transplant protocols for hematological malignancies. She has recently published clinical outcomes on patients with Leukemias and lymphomas who relapsed after allogeneic transplantation and were treated with CTLA4 IG monoclonal antibodies to enhance T cells immunity. She has extensive experience in stem cells, transplantation for several devastating diseases including Sickle cell Disease and B-Thalassemia, Lupus etc.

×Close

Dr. Evan Y. Snyder, Director, Program in Stem Cell and Regenerative Biology

Professor, Sanford | Burnham Medical Research Institute
Director, Program in Stem Cell and Regenerative Biology
Director, Stem Cell Research Center
Associate Member, Sanford Children’s Health Research Center
Faculty Physician, Department of Pediatrics University of California, San Diego
Faculty, Biomedical Sciences Graduate Program University of California, San Diego
Scientific Steering Committee Sanford (San Diego) Consortium for Regenerative Medicine

Dr. Evan Y. Snyder, M.D. Ph.D. has been a Professor and a Director of the Stem Cells and Regeneration program at Burnham Institute for Medical Research since 2003. Dr. Snyder He served as the Chief Resident in Medicine from 1984 to 1985 and Chief Resident in Neurology since 1987 at Children's Hospital-Boston. In 1989, he became an attending physician in the Department of Pediatrics (Division of Newborn Medicine) and Department of Neurology at Children's Hospital-Boston, Harvard Medical School. From 1985 to 1991, concurrent with his clinical activities, he conducted postdoctoral research as a fellow in the Department of Genetics, Harvard Medical School. In 1992, Dr. Snyder was appointed an instructor in neurology (neonatology) at Harvard Medical School and was promoted to assistant professor in 1996. He maintained lab spaces in both Children's Hospital-Boston and at Harvard Institutes of Medicine/Beth-Israel Deaconess Medical Center. He serves as a Member of Scientific Advisory Board at OncoCyte Corporation, RxGen Inc., American Stem Cell, Inc. and California Stem Cell, Inc. Dr. Snyder is a Fellow of the American Academy of Pediatrics (FAAP). He also received training in Philosophy and Linguistics at Oxford University. Dr. Snyder earned his M.D. and his Ph.D. in Neuroscience from the University of Pennsylvania in 1980. He completed residencies in pediatrics and neurology at Children's Hospital-Boston and postdoctoral research at Harvard Medical School.

×Close

Dr. Kamal Patel, M.D

Dr. Patel has been working with pioneers in the field of oncology, personalized medicine, and stem cell transplant for nearly 10 years. He is a member of the American College of Physician Executives, a fellow at Doximity, and an assistant professor in the department of radiology at the Chicago Medical School. He has given presentations and speeches to a wide variety of audiences, including physicians, clinicians, and the press (FOX News, at the NFL Chicago Bears Press Conference, and others). He teaches 2nd year medical students at the Chicago Medical School. He works relentlessly to find treatment options and cures for cancer patients. His goal is to leverage his experience, expertise, and resources to ensure the safest and most effective treatments of GIOSTAR patients around the world.

×Close

Mr. Tejas Mehta – Vice President

Mr Tejas Mehta comes from one of the foremost families of philosophers and pioneer businessmen in the state of Gujarat, India.

On the behalf of the California State Senate and Indo-American Trade and Commerce Council, he was honored and received a Certificate of Recognition for promoting the sister state relationship in 2001.He was commended for his efforts in establishing closer economical and cultural ties between California, USA and Gujarat, India by Mr. John H. Burton-Senator, in the presence of one of the longest serving speaker of the senate, Hon'ble Mr. Willy Brown Jr.

He also serves as the Executive Trustee of the GIOSTAR Foundation.

×Close

Mr. Siddharth Bhavsar, MS, MBA - Chief Operating Officer

Mr. Siddharth Bhavsar has over 10 years of experience working on key projects in a broad spectrum of industries including Healthcare, Life Sciences, High-tech, Software & Internet, with a wide range of companies including Fortune 500 companies (Philips Healthcare,General Electric,Microsoft, Hitachi), government (National Institute of Health), Start-Ups and Non-Profits. His projects covered corporate finance, developing business plans, raising venture capital, performing investment analysis, strategy development, business process improvement, operations, marketing, M&A, partnership development and post merger integration. His international projects footprint spans USA, India, Netherlands, China, Japan and New Zealand. He also has experience of working in Private Equity, launching international operations for companies and turning around failing organizations. He has consistently been a recipient of a number of awards for excellence in his academic & professional pursuits including a National Merit Scholarship, Academic Achievement award, Philips Ovation Award, Philips Healthcare trasPHorm award among others. He also holds a patent in Cardiology Information Systems. He has an M.S in Computer Science from USC and an MBA from UCLA Anderson School of Management where he has held a number of Director level positions and was most recently an officer for Technology Incubation on the Board of Entrepreneurs' Association.

×Close

Mr. Sandeep Seth - Legal Adviser

Sandeep Seth is an Attorney and an Aerospace Engineer who has been counseling clients in legal matters since 1992. Mr. Seth's practice emphasizes intellectual property, in particular patent litigation and licensing. Mr. Seth is licensed to practice in Texas and California and is also registered to practice before the United States Patent and Trademark office.

×Close

Mr. Ferdinand Melendres – Vice President of Business Development

Mr. Melendresis serving as Vice President of Business Development. He entails identifying, qualifying and closing business deals through relationship building. He pursues international leads and amplifies company relation between client and associates by increasing the economic welfare of all stakeholders. Mr. Melendres is a Vice President implementing 'best practices' and fostering business growth in the highly competitive global environment of Procurement, Management and General Construction industries. He serve GIOSTAR's mission by delivering strategic vision, operational development, and regulatory expertise in the different areas of the globe. His hands-on experience working in health care facilities helped him understand the people suffering from degenerative diseases, and provided him a platform to pursue his passion of making a positive difference in people's life through the vehicle of stem cell technology. Mr. Melendres holds a degree in Civil Engineering.

×Close

Mr. Ashvin Shah – Director

Mr. Ashvin Shah is an esteemed citizen of Ahmedabad, Gujarat, India. He is an entrepreneur and associated with several social and educational welfare/reform activities. A humanitarian and nationalist, Mr. Shah is the Chairman of GIOSTAR/SAVIOUR hospital, the first dedicated stem cell treatment hospital in the world located in Ahmedabad, Gujarat, India.

×Close

Mr. Pramit Maakoday - Director, IT and E-Healthcare

Mr. Maakoday is serving as a Director of IT and E-Healthcare and bridging the gap between technology, medical science and patient care. He has over fifteen years of experience working with various IT related project around the world and managing clients from USA, UK, Ireland, and India. He is an Honorary Vice President of Computer Society of India for international region, with over hundred thousand members. He is also actively involved in major ICT4D initiatives EKISAAN foundation, and One Laptop Per Child Foundation. He is also an honorary Director of Next Generation Foundation, USA. He has been recipient of several awards for his initiatives including philanthropic award for large ICT4D and Digital Literacy Initiatives, NRI Gaurav award from IT minister of India and Chief Minister of Madhya Pradesh, Youth Parliament and Yuva Niti Nirdharan winner (Young India Policy Initiative). He is very active in local and international political arena and has been a great asset to GIOSTAR for its worldwide expansion efforts.

×Close

Professor, Stem cell Transplantation
Cancer Center, School of Medicine
University of California San Diego, USA

Dr. Carrier, a Stanford graduate, is a world-renowned clinician and research specialist in stem cells transplantation. She has been trained in the world famous transplant center at the University of California San Francisco, and spend last 15 years working on research and clinical aspects of transplantation. She has developed a unique in utero stem cell transplantation model and was Principal Investigator on prenatal transplantation model in humans. She has also developed unique serum-free culture conditions for culturing human embryonic stem cells and differentiated them into erythrocyte precursors. She actively participates in national clinical transplant protocols for hematological malignancies. She has recently published clinical outcomes on patients with Leukemias and lymphomas who relapsed after allogeneic transplantation and were treated with CTLA4 IG monoclonal antibodies to enhance T cells immunity. She has extensive experience in stem cells, transplantation for several devastating diseases including Sickle cell Disease and B-Thalassemia, Lupus etc.

×Close

Director
Optimer Pharmaceuticals Inc.
San Diego, California, USA

Dr. Om Srivastava received his degree in Medicinal Chemistry in 1983 and joined Prof. Ole Hindsgaul group at University of Alberta, Canada. In 1987, he joined Alberta based company, ChemBioMed Ltd., where as a Senior Research Scientist and a group leader he was involved in the synthetic and development aspects of complex carbohydrates with the major focus on blood group determinants, tumor associated antigens, cell adhesion molecules for selectins. He has worked at Alberta Research Council and has led a program to develop the treatment of Arthritis, Asthma, Bacterial and Viral diseases. In 1994, he was honored as the Distinguished Scientist at Alberta Research Council and was responsible for the development of Science and Technology for the Province of Alberta, Canada. He has more than 75 Scientific Publications, Patents and Conference Proceedings. He has presented several invited lectures in International Conferences.

×Close

Chief and Associate Director for research
Aquatic Genomics Research Center
National Research Institute of Science 2-12-4 Fukuura, Kanazawa
Yokohama 236-8648, Japan

Dr. Ichiro Oohara is one of the leading scientists in the field of genomics and proteiomics, who has the expertise on the genetic regulation of the development of organism. He is a pioneer in the manipulation of the genes to direct the genes expressions. He has been awarded with several Japanese and international scientific awards. He directs and advises GIOSTAR team to identify the specific target genes, which may help the Stem Cells to differentiate towards the specific tissue lineage.

×Close

Professor,
Department of Ophthalmology,
University Eye Hospital Heidelberg,
INF 400, 69120 Heidelberg, Germany

Dr. Beutelspacher is one of the leading clinician in the world who works on the retinal transplant and eye related malignancies. He reported for the first time retinal venous vascular occlusion as the primary manifestation of Paroxysmal nocturnal hemoglobinuria (PNH) and suggested that hematopoietic Stem cell may be a cure of the disease. He holds membership of several academic and clinical organizations and has received several scientific awards. He is currently working on the stem cell program to develop the stem cell therapy for retinal differentiation from the embryonic stem cell. His continued findings have been published in several high impact and international clinical journals.

×Close

Senior Scientist
Department of Immunology, Faculty of Medicine,
Imperial College London, Hammersmith Campus, London, UK.

Dr. Pillai is a renowned scientist in the field of oncology and is currently working as a Senior Scientist at the world famous Imperial College at London. He has more than 20 years of experience in the field of cancer research. He was one of the pioneers to show the therapeutic value of curcumin and suggested that curcumin may be used as a potential anticancer agent that can be employed to kill the lung cancer cells. He has acquired vast and diverse working experience by working at various institutes and industries in different countries including India, USA and UK. In addition, Dr. Pillai has served as chair of Ealing Hospital PPIF (London), Chief Editor/Executive Editor/member of editorial board of different scientific journals and Governor of different schools in USA and UK. He is currently advising the GIOSTAR team to study the cancer stem cell and trying to develop an agent which can manipulate the cancer stem cell to cure several cancers.

×Close

Radiologist
Nansei Hospital
Gokaso, Nansei, Mie-510, Japan

Dr. Ogawa is a leading radiologist at Nansei hospital in Japan. He has more than 25 years of working experience in the field of radiology and is an expert of multiple scanning techniques including CAT, PET, CITI, NMR.

×Close

Professor
Department of Surgery, Division of Surgical Oncology
Vanderbilt University Medical Center,
Nashville, Tennessee, USA

Dr. Singh is a well-recognized scientist in the field of colon cancer. He, for the first time showed a direct correlation between growth factor signaling and cell junction protein, claudins and thus a causative role in the development and progression of colon cancer. He has published his research findings in several well-known international journals of high impact. He has been awarded by International Research fellowship award from Human Frontier Science Program Organization (HFSPO), France, and is an active member of American Society of Nephrology, American Gastrointestinal Association, and Vanderbilt Ingram Cancer Center etc.

×Close

Senior Scientist
Department of Neurobiology
School of Medicine, University of California Irvine
Irvine, California, USA.

Mr. Sharp has more than 15 years of experience in biological sciences with hands-on experience being a bench scientist. He is developing ES cell based therapy for spinal cord injury and other neural diseases. He is an expert of Human ES cell culture. He developed the program of mass production of Human ES cell for therapeutic use. He has expertise in development of cGMP cell culture (e.g., manage IQ/OQ/PQs), Intellectual property management (e.g., compile patents for submission to USPTO), Oversight of pre-clinical/non-clinical studies (e.g., qualify CROs for toxicology studies), Regulatory compliance management (e.g., manage pre-IND discussions), Clinical development (e.g. develop inclusion/exclusion criteria for patients), Business development (e.g., valuation of an in-license candidate).

×Close

Senior Scientist
Department of Medicine
Case Western Reserve University
Division of Nephrology
Cleveland, Ohio, USA.

Dr. Mishra works on cell signaling pathways involved in kidney and lungs cells. Cell signaling pathways induced by diabetes in kidney cells lead to extra-cellular matrix deposition, which in turn, leads to decline in renal function. He is leading a team which is trying to investigate which genes are induced by diabetes in kidney cells during diabetes and which proteins can be used as biomarkers in progressive kidney diseases. Based on his bioinformatics data and some preliminary clinical data in human, a set of ten potential biomarkers has been recognized that will help detect the early onset of decline in kidney functions. He is one of the leaders in his research field and has published several leading research findings in the high rated medical journals.

×Close

Professor
Beth-Israel Deaconess Medical Center
Harvard Medical School,
Boston, MA-02148, USA.

Dr. Shavali, a leading scientist from the world renowned Harvard Medical Center has been awarded with several national and international awards including Research Associate-ship award from Boston University Medical Center, Boston, MA, USA, International science award from the Japan Society for the Promotion of Science, Tokyo, Japan. Dr. Shavali has unique expertise in the areas of neurobiology and neurodegenerative diseases. He demonstrated, for the first time, that endogenously produced dopamine-derived neurotoxins can cause dopamine neuron death in Parkinson's disease models. He has also shown that alpha-synuclein accumulates in the mitochondria of alpha-synuclein over-expressing cells under oxidative stress conditions. His studies provided evidence that alpha-synuclein accumulation causes mitochondrial defects and ultimately lead to demise of dopamine neurons in Parkinson's disease. He also demonstrated that growth factors like IGF-1 can protect dopamine neurons from neurotoxin-induced oxidative stress.

×Close

Associate Scientist
Cancer Center,
University of California San Diego, California, USA

Dr. Balaian has excellence in the stem cell biology with expertise of blood related diseases and blood cancer. She has 20 years of working experience with Stem cell and cancer. Her research has been focused on developing the mesenchymal stem cells model that allows the investigation of the Hematopoietic Stem cell (HSC) and leukemia stem cells homing effects and regulation of their growth. HSC as well as leukemia stem cells and metastatic tumor cells reside in bone marrow niches to receive growth, survival and differentiation signals. Their localization and migration between niches depends on cell-cell and cell-matrix interactions, which result from the cooperation of cytokines, chemokines and adhesion molecules. She leads studies of migration, adhesion, proliferation, apoptosis, differentiation, cytokine production and underlying gene expression and signal transduction to make it more effective for stem cell clinical therapy for blood diseases.

×Close

Udai P. Singh, Ph.D.
Assistant Professor of Pathology, Microbiology and Immunology
Assistant Director, Flow Cytometry Facility
University of South Carolina School of Medicine
Columbia, South Carolina, USA

Dr. Udai Singh is in academia since 22 years. Presently Dr. Singh serving as Assistant Director for Sterile Cell Sorting Core facilities at University of South Carolina School of Medicine,Columbia USA. Dr. Singh past training and research work have been mostly related to cellular and mucosal immunology, especially on inflammatory bowel disease (IBD) and inflammation.

Dr. Singh have published over 60 peer-reviewed papers most of them in the area of inflammation as it relates to, autoimmune disease, intestinal inflammation and immune responses. Dr. Singh demonstrated for the first time that anti-CXCL10 (chemokine) Ab treatment abrogated colitis in IL-10-/- mice. Dr. Singh have extensive experience in studying the immune response and alsodemonstrate that polyphenols such as resveratrol can enhance SIRT-1 expression in the lamin propria lymphocytes and down regulate NF-kB activation, leading to decreased inflammation in the colon.

Dr. Singh presently investigating the mechanisms underlying the effects of CAM compounds on inflammation and IBD. Dr. Singh research work has resulted in several invited lectures, multiple publications and a patent. Due to expertise in immunology, gaining knowledge in area of CAM compounds, Dr. Singh works as principal investigator in many research proposals. Dr. Singh is directing the cell-processing unit of GIOSTAR.

Stem cell treatment of Multiple Sclerosis

Multiple sclerosis (MS) is a chronic neurological disorder that affects the central nervous system (brain and spinal cord). The disease process results in inflammation and damage to myelin (the insulating tissue for nerve fibers) and other cells within the nervous system.

Because myelin aids the conduction of nerve signals, damage to myelin results in impaired nerve signaling and may impair normal sensation, movement, and thinking. This damage occurs in patches that appear as distinct lesions on magnetic resonance imaging (MRI). The patches cause different symptoms, depending on their location within the nervous system.

The GIOSTAR- Multiple Sclerosis treatment

There are treatments available that may slow its progression and alleviate associated symptoms. Stem cell therapy is among these treatment options and Giostar provide the therapy for this disease.

Stem cell treatment of Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS), also called Lou Gehrig's disease or Motor Neuron Disease, is a rapidly progressive, invariably fatal neurological disease that attacks the nerve cells (neurons) responsible for controlling the voluntary muscles. In ALS, both the upper motor neurons and the lower motor neurons degenerate or die, ceasing to send messages to muscles. Unable to function, the muscles gradually weaken, waste away (become atrophic), and typically twitch (fasciculate).

Eventually the inability of the brain to drive and/or control voluntary movement is the triggering mechanism. Individuals with ALS lose their strength and the ability to move their arms, legs, and body. When muscles in the diaphragm and chest wall fail, individuals finally lose the ability to breathe without ventilatory support.

The disease does not affect a person's ability to see, smell, taste, hear, or recognize touch, and it does not usually impair a person's thinking or other cognitive abilities. However, several recent studies suggest that a small percentage of patients may experience problems with memory or decision-making, and there are subtypes that may even lead to a form of dementia.

Stem cell treatment of Sickle Cell Anemia

Sickle-cell disease, or sickle-cell anaemia (or drepanocytosis), is a life-long blood disorder characterized by red blood cells that assume an abnormal, rigid, sickle shape. Sickling decreases the cells' flexibility and results in a risk of various complications. The sickling occurs because of a mutation in the hemoglobin gene. Life expectancy is shortened, with studies reporting an average life expectancy of 42 and 48 years for males and females, respectively.

Sickle-cell disease, usually presenting in childhood, occurs more commonly in people (or their descendants) from parts of tropical and sub-tropical regions where malaria is or was common. One-third of all indigenous inhabitants of Sub-Saharan Africa carry the gene, because in areas where malaria is common, there is a survival value in carrying only a single sickle-cell gene (sickle cell trait). This disease can be cured using stem cell derived blood stem cell. GIOSTAR has derived the hematopoietic stem cell (blood stem cell) and able to treat this disease using its most advanced method.

Stem cell treatment of Leukemia

Leukemia is a cancer of the blood or bone marrow and is characterized by an abnormal proliferation (production by multiplication) of blood cells, usually white blood cells (leukocytes). Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader group of diseases called hematological neoplasms. GIOSTAR scientists have successfully differentiated the blood stem cells, which can change the defective blood stem cells of the body and make healthy blood cells to remove the cancerous blood cells.

Stem cell treatment of Beta-thalassemia

Thalassemia is an inherited autosomal co-dominant blood disease. In thalassemia, the genetic defect results in reduced rate of synthesis of one of the globin chains that make up hemoglobin. Reduced synthesis of one of the globin chains can cause the formation of abnormal hemoglobin molecules, thus causing anemia, the characteristic presenting symptom of the thalassemias. GIOSTAR has ability to generate the blood stem cells, which can replace the defective blood stem cell of body and make the individual normal and healthy.

×Close

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nunc nec nibh diam, id luctus nisl. Etiam tincidunt tellus sed nisl malesuada interdum. Suspendisse potenti. Proin eu lacus eget sem scelerisque condimentum hendrerit at ante. Suspendisse a ligula est. Proin a urna vitae orci sodales pellentesque sed non lacus. Donec aliquet ullamcorper lectus, quis convallis sem scelerisque quis. Integer nec nulla eu ligula ultricies condimentum. Nullam magna diam, viverra in posuere ac, sagittis nec lorem. Cras vel risus risus. Sed sit amet risus adipiscing ligula placerat bibendum. Aliquam nulla quam, varius ut mattis id, lobortis non nunc. Aliquam erat volutpat. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Nulla lacinia enim sit amet libero pulvinar sed luctus ante ullamcorper.

Stem cell therapy for Alzheimer's disease

Alzheimer's disease is the most common form of senile dementia. It is typically associated with a slow but progressive loss of nerve cells and nerve cell contacts. The onset of the disease is insidious, and the first symptoms to manifest are impaired memory and orientation.

As the disease progresses, the sufferer's mental faculties deteriorate and, after a few years, patients require help to perform everyday tasks and are no longer able live on their own. One particularly disturbing aspect of this stage of the disease for family and friends is that the patient often doesn't recognize close relatives or perhaps even their partner. People with Alzheimer's disease also gradually lose their personality.

It is not known what causes Alzheimer's disease, although the brains of Alzheimer's patients do demonstrate typical microscopic changes: Extracellular protein depositions –called amyloid plaques– and fibrous intracellular protein aggregations –called neurofibrillar tangles. It seems impossible to cure Alzheimer's disease because dead nerve cells cannot be regenerated.

The GIOSTAR- Alzheimer's disease therapy

Giostar is under the process of developing the therapy for AD.The stem cells are first collected from a patient's bone marrow extracted from the hipbone (iliac crest) then implanted back into the body a few days later. Prior to re-implantation of the cells, the bone marrow is processed in one of our labs, where the quantity and quality of the stem cells is also checked.

These re-injected stem cells may transform into new cells; rejuvenating or replacing damaged tissue and/or nerves.

The goal of the therapy is to slow down or stop the regression of the symptoms of Alzheimer's disease.

×Close

Amyotrophic Lateral Sclerosis (ALS), also called Lou Gehrig's disease or Motor Neuron Disease, is a rapidly progressive, invariably fatal neurological disease that attacks the nerve cells (neurons) responsible for controlling the voluntary muscles. In ALS, both the upper motor neurons and the lower motor neurons degenerate or die, ceasing to send messages to muscles. Unable to function, the muscles gradually weaken, waste away (become atrophic), and typically twitch (fasciculate).

Eventually the inability of the brain to drive and/or control voluntary movement is the triggering mechanism. Individuals with ALS lose their strength and the ability to move their arms, legs, and body. When muscles in the diaphragm and chest wall fail, individuals finally lose the ability to breathe without ventilatory support.

The disease does not affect a person's ability to see, smell, taste, hear, or recognize touch, and it does not usually impair a person's thinking or other cognitive abilities. However, several recent studies suggest that a small percentage of patients may experience problems with memory or decision-making, and there are subtypes that may even lead to a form of dementia.

The GIOSTAR- Amyotrophic Lateral Sclerosis therapy

No cure has been found for ALS yet. The United States Federal Drug Administration (FDA) has approved the first drug for the treatment of the disease: Riluzole. Riluzole is believed to reduce damage to motor neurons and prolongs survival by several months, mainly in those patients with swallowing difficulty.

Stem cell therapy may be used to attenuate the severity of some symptoms, improve a patient�s quality of life and slow down chronic consequences of ALS. The exact process behind the workings of the stem cells re-introduced to the patient�s body is not yet fully understood.

The stem cells are first isolated from a patient�s bone marrow extracted from the hipbone (iliac crest) then implanted back into the body a few days later. Prior to re-implantation of the cells, the bone marrow is processed in one of our labs, where the quantity and quality of the stem cells is also checked.GIOSTAR is under the process of developing this therapy.

Stem cell treatment of Anti-aging

Stem cell has the potential to regenerate all kind of cells of body. GIOSTAR scientists have developed the technology to differentiate Stem cells into neural cell, blood cells, skin cell and hair cells. These cells may be used to replace the old cells of body with new and young cells to treat the aging related diseases.

Stem cell therapy for Autism

Autism is a highly variable neurodevelopmental disorder that first appears during infancy or childhood, and generally follows a steady course without remission. Overt symptoms gradually begin after the age of six months, become established by age two or three years, and tend to continue through adulthood, although often in more muted form. It is distinguished not by a single symptom, but by a characteristic triad of symptoms: impairments in social interaction; impairments in communication; and restricted interests and repetitive behavior. Other aspects, such as atypical eating, are also common. GIOSTAR has developed the Stem cell based technology which helps to regenerate the damage neural cells and makes new blood vessels to supply oxygen in the brain to recover form autism.

Stem cell therapy for Cerebral palsy

Cerebral palsy refers to a group of non-progressive, non-contagious conditions that cause physical disability and applies to the cerebrum in the brain and the disorder of movement.

The brain damage normally doesn't worsen, but secondary diseases are very common. Most notable are various orthopedic difficulties and motor disorders, arthritis and osteoporosis.

Stem cell therapy for Erectile Dysfunction

Erectile Dysfunction, commonly referred as 'impotence', is the repeated inability to get or keep an erection firm enough for healthy coitus. The word 'impotence' may also be used to describe other reproductive problems that interfere with coitus and reproduction, such as lack of libido and problems with ejaculation or orgasm. The term 'erectile dysfunction' specifies that other problems are not involved.

Damage to nerves, arteries, smooth muscles, and fibrous tissues, often as a result of a disease, is the most common cause of erectile penile dysfunction. Diseases such as diabetes, kidney diseases, chronic alcohol consumption, multiple sclerosis, atherosclerosis, vascular diseases, and neurologic diseases, account for about 70 percent of erectile dysfunction cases. Diabetes is one of the most common metabolic syndromes of the developed societies and spreading in developing societies. Thirty to 50 percent of men with diabetes experience erectile dysfunction.

Stem cells have the potential to transform into new tissue, replacing damaged tissue, like nerves or arteries, enabling your penis to erect. The goal of this treatment is to repair damaged tissue and to reactivate existing cells with the ultimate goal of improving vascularization to facilitate normal erections.

Stem cell treatment of Failed Back Surgery Syndrome

Both terms mean the same: after back surgery, the patient suffers from chronic back pain. The pain may be concentrated in the area operated on, or may radiate to the legs.

The pain persists, despite various therapies using either drugs or invasive treatments like denervation or implantation of spinal cord simulators. Eventually, the patient ends up being labeled "untreatable" and is "treated" using pain-suppressing drugs.

The GIOSTAR- treatment of Postnucleotomy Syndrome

The GIOSTAR- offers a highly advanced combination of Percutaneous Laser Disc Decompression and Regenerative Disc Repair.

Percutaneuous Laser Disc Decompression (PLDD) is a new laser-assisted disc decompression technique, where the laser is used to vaporize a part of disk or its scarred tissue. It is one of the newest forms of "minimally invasive surgery".

Regenerative Disc Repair is done using the GIOSTAR-'s exclusive adult stem cell therapy. Autologous stem cells, (out of patient's own body) are implanted through the same tube that is used to guide the laser. The stem cells thus arrive into exactly the right space to start their regenerative work.

Stem cell treatment of Liver diseases

Cirrhosis is a consequence of chronic liver disease characterized by replacement of liver tissue by fibrous scar tissue as well as regenerative nodules (lumps that occur as a result of a process in which damaged tissue is regenerated), leading to progressive loss of liver function. Cirrhosis is most commonly caused by alcoholism, hepatitis B and C, and fatty liver disease but has many other possible causes. Some cases are idiopathic, i.e., of unknown cause.

Ascites (fluid retention in the abdominal cavity) is the most common complication of cirrhosis and is associated with a poor quality of life, increased risk of infection, and a poor long-term outcome. Other potentially life-threatening complications are hepatic encephalopathy (confusion and coma) and bleeding from esophageal varices. Cirrhosis is generally irreversible once it occurs, and treatment generally focuses on preventing progression and complications. In advanced stages of cirrhosis the only option is a liver transplant. GIOSTAR has the technology to use stem cell to regenerate the new liver cells using Stem cell derived liver progenitor cell transplantation.

Stem cell treatment of Macular Degeneration

Mascular degeneration is a retinal degenerative disease that causes progressive loss of central vision. The risk of developing Macular degeneration increases with age. The disease most often affects people in their sixties and seventies. Macular degeneration is the most common cause of vision loss in individuals over the age of fifty.

The macula is the central portion of the retina responsible for perceiving fine visual detail. Light sensing cells in the macula, known as photoreceptors, convert light signals into electrical impulses which are then transferred to the brain via the optic nerve. Central vision loss from Macular degeneration occurs when photoreceptor cells in the macula degenerate.

These re-injected stem cells have the potential to transform into multiple types of cells and are capable of regenerating damaged tissue. Our innovative stem cell treatments use the self-healing potential of each patient's own body to stimulate regeneration or repair.

We believe that the retro-bulbar injection of autologous stem cells might first prevent the progression of dry and wet macular degeneration by reducing the Drusen deposits in the retinal pigment epithelium beneath the macula. It might also prevent the destruction of the photoreceptors in both the dry and wet type, by reactivating proper micro-vessel activity and reducing the abnormal blood vessel growth beneath.

×Close

Stem cell treatment of Multiple Sclerosis

Multiple sclerosis (MS) is a chronic neurological disorder that affects the central nervous system (brain and spinal cord). The disease process results in inflammation and damage to myelin (the insulating tissue for nerve fibers) and other cells within the nervous system.

Because myelin aids the conduction of nerve signals, damage to myelin results in impaired nerve signaling and may impair normal sensation, movement, and thinking. This damage occurs in patches that appear as distinct lesions on magnetic resonance imaging (MRI). The patches cause different symptoms, depending on their location within the nervous system. Giostar scientists have developed the treatment for this disease using adult stem cells.

Stem cell treatment of Neuropathy

Neuropathy is a medical term referring to disorders of the nerves of the peripheral nervous system (specifically excluding encephalopathy and myelopathy, which pertain to the central nervous system). It is usually considered equivalent to peripheral neuropathy, which is defined as deranged function and structure of peripheral motor, sensory, and autonomic neurons, involving either the entire neuron or selected levels. According to some sources, a disorder of the cranial nerves can be considered a neuropathy. GIOSTAR has developed the technology to generate the functional neural cells from Stem cells which has ability to repair the damage neural cells may cure the patient.

Stem cell treatment of Osteoarthritis

Osteoarthritis is a degenerative joint disease that mostly affects the cartilage. Cartilage is the slippery tissue that covers the ends of bones in a joint. Healthy cartilage allows bones to glide over each other. It also helps absorb shock of movement.

In osteoarthritis, the top layer of cartilage breaks down and wears away. This causes the bones under the cartilage to rub together. The rubbing causes pain, swelling, and loss of motion of the joint. Over time, the joint may lose its normal shape. Also, bone spurs may grow on the edges of the joint. Bits of bone or cartilage can break off and float inside the joint space, which causes more pain and damage.

Stem cell and possible therapy for Paralysis

Paralysis is the complete loss of muscle function for one or more muscle groups. Paralysis can cause loss of feeling or loss of mobility in the affected area. Paralysis is most often caused by damage to the nervous system, especially the spinal cord. Major causes are stroke, trauma, poliomyelitis, amyotrophic lateral sclerosis (ALS), botulism, spina bifida, multiple sclerosis, and Guillain-Barré syndrome. Stem cells have the ability to regenerate the damage neural and muscle cells therefore have the potential to cure the disease. GIOSTAR scientists have differentiated the progenitors of neural and muscle cells from stem cell. These cells may repair the damaged caused by paralysis and cure the disease.

Stem cell and possible therapy for Parkinson's disease

Parkinson's disease is a movement disorder and it is characterized by muscle rigidity, tremor and a slowing of physical movement. This is caused by the degenerative character of the disease, which primarily affects the central nervous system and leads to an impairment of motor and speech skills and a number of other body functions. Giostar has differentiated the dopaminerzic neuron in the lab with high purity and under the process of developing the treatment for this devastating disease.

Stem cell treatment of Retinal transplant

The retinal pigment epithelium (RPE) is a layer of pigmented cells sandwiched between the visual retinal cells, called photoreceptors, and the nourishing blood vessels at the back of the eye. The RPE provides essential support to the retinal photoreceptors and is critical for normal vision. Deterioration of the RPE plays a central role in the progression of diseases such as age-related macular degeneration and sub-types of retinitis pigmentosa. These conditions are associated with a progressive loss of vision that often leads to blindness. GIOSTAR has the ability derive RPE-like cells from ES cell, which is identified by their characteristic black pigment, exhibited multiple biological properties and genetic markers that define authentic RPE cells. Further, the cells successfully delayed deterioration of retinal structure and function when they were transplanted into eye. GIOSTAR is developing the technology to treat the blindness related with retinal degeneration.

Stem cell treatment of Spinal Cord Injuries

Spinal cord injuries usually begin with a sudden, traumatic blow to the spine that fracture or dislocate vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue.

Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crushes and destroys the axons, extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery; others will result in complete paralysis. Giostar has developed the way to generate neural progenitors cells which shows significance in treatment of spinal cord injuries.

Stem cell therapy for Stroke

A cerebrovascular accident is also known as a stroke. A stroke is a life-threatening event in which part of the brain is deprived of adequate oxygen.

There are two kinds of strokes:

* Ischemic strokes occur when the blood supply to the brain is interrupted, usually by a blood clot originating from the carotid arteries. These arteries feed the head and brain with oxygen-rich blood. The cause is usually atherosclerotic plaques in one of the arteries.

* Hemorrhagic strokes occur when there is bleeding into or around the brain. Giostar has developed a method to generate high purity neural progenitors cells which shows significance in treatment of stroke.

Stem cell treatment of Skin Burns

Burn injury has been reported to be an important cause of morbidity and mortality in many countries. It leads to a loss of integrity of the skin, which protects us from water loss, temperature change, radiation, trauma and infection. The main sources of stem cells that might be used for repair and regeneration of injured skin tissue are embryonic stem cells (ESCs) and adult stem cells. GIOSTAR has the ability to differentiate Bone Marrow Stem Cells and Mesenchymal Stem cells into epidermal cells and fibroblasts in vitro, and can accelerate the skin wound repair.

Stem cell treatment of Spinal muscular atrophy (SMA)

Spinal Muscular Atrophy (SMA) is a neuromuscular disease characterized by degeneration of motor neurons, resulting in progressive muscular atrophy (wasting away) and weakness. The clinical spectrum of SMA ranges from early infant death to normal adult life with only mild weakness. These patients often require comprehensive medical care involving multiple disciplines, including pediatric pulmonology, pediatric neurology, pediatric orthopaedic surgery, pediatric critical care, and physical medicine and rehabilitation; and physical therapy, occupational therapy, respiratory therapy, and clinical nutrition.

In all of its forms, the primary feature of SMA is muscle weakness, accompanied by atrophy of muscle. This is the result of denervation, or loss of the signal to contract, that is transmitted from the spinal cord. This is normally transmitted from motor neurons in the spinal cord to muscle via the motor neuron's axon, but either the motor neuron with its axon, or the axon itself, is lost in all forms of SMA.

The features of SMA are strongly related to its severity and age of onset. SMA caused by mutation of the SMN gene has a wide range, from infancy to adult, fatal to trivial, with different affected individuals manifesting every shade of impairment between these two extremes. Many of the symptoms of SMA relate to secondary complications of muscle weakness. GIOSTAR has developed the techniques to differentiate the Stem cells into the high purity motor neuron progenitor cells. These cells have ability to regenerate the new and healthy neurons after transplantation and may cure the disease.

Stem cell treatment of Crohn

Crohn's disease is an autoimmune disease in which the body's own immune system attacks the gastrointestinal tract, resulting in a lifetime of severe diarrhea and stomach pain for its sufferers. Severe is an understatement: for the worst sufferers Crohn's disease can mean 20-30 painful and embarrassing diarrhea visits to the toilet everyday. Treatment is sometimes effective for mild cases of the disease, but for the most severe cases treatment options are very limited. Giostar has ability to treat the Chrohn's diseas using stem cell transplant.

The defective immune cells are inactivated by Initial Chemotherapy. Stem Cells will be collected by means of Apheresis from peripheral blood. Giostar clinician uses the Autologous Stem-Cell Transplant to reset the immune system, leading to remission or reduction of the abnormal inflammatory process of Crohn's disease.

Stem cell treatment of Lymphoma

Lymphoma is a general term for cancer in the lymph system. The lymph system is made up of many cells and organs, including the lymph nodes, thymus gland, spleen, and liver. This system produces B-Cells and T-Cells, which make up your body's immune system. Since these cells travel between the lymphatic and circulatory system while fighting infections and viruses, lymphomas are blood-related cancers.

There are two main categories of lymphomas: Hodgkin's lymphoma (aka Hodgkin's disease or Hodgkin lymphoma) and Non-Hodgkin's lymphomas (NHL). Hodgkin's disease is a very specific type of cancer that involves a mutation in Reed-Sternberg cells.

Non-Hodgkin's Lymphomas involve mutations in the body's B-Cells and T-Cells. B-Cell Lymphomas account for over 80% of all NHL. T-Cell Lymphomas make up the rest. Giostar has ability to change the old immune system with the using stem cell transplantation.

Stem cell treatment of Scleroderma

Scleroderma is a chronic systemic autoimmune disease (primarily of the skin) characterized by fibrosis (or hardening), vascular alterations, and autoantibodies. There are two major forms:

Limited systemic sclerosis/scleroderma involves cutaneous manifestations that mainly affect the hands, arms and face. Previously called CREST syndrome in reference to the following complications: Calcinosis, Raynaud's phenomenon, Esophageal dysfunction, Sclerodactyly, and Telangiectasias. Additionally, pulmonary arterial hypertension may occur in up to one third of patients and is the most serious complication for this form of scleroderma.

Diffuse systemic sclerosis/scleroderma is rapidly progressing and affects a large area of the skin and one or more internal organs, frequently the kidneys, esophagus, heart and lungs. This form of scleroderma can be quite disabling. There are no treatments for scleroderma itself, but individual organ system complications are treated. Other forms of scleroderma include systemic sine scleroderma, which lacks skin changes, but has systemic manifestations, and two localized forms which affect the skin, but not the internal organs: morphea, and linear scleroderma. Giostar team has developed the treatment for this disease using adult stem cell transplant.

Stem cell treatment of Vasculitis

Vasculitis refers to a heterogeneous group of disorders that are characterized by inflammatory destruction of blood vessels. Both arteries and veins are affected. Lymphangitis is sometimes considered a type of vasculitis. Vasculitis is primarily due to leukocyte migration and resultant damage.

Stem Cell Transplant is often preceded by high-dose chemotherapy and/or radiation, which destroys both your diseased and healthy cells. You must be in the hospital to avoid exposure to infection. In case of autologous transplant, Stem cells are collected from the patient's blood or bone marrow and stored until time of transplant. Whereas, in allogeneic transplant, Stem cells are collected from the blood or bone marrow of a relative, or a non-related donor. After transplant, patient will have to remain in the hospital for about three to four weeks. In addition, you will need to adhere to a long-term drug therapy regimen and an intensive follow-up period. Giostar has ability to treat this disease using adult stem cell.

Stem cell treatment of Diabetes type 1

The autoimmune reaction of the body to the pancreatic beta cells in the islets of Langerhans and the resulting destruction of these beta cells, cause an immediate insuline deficiency, resulting in type 1 diabetes.

Diabetes mellitus type 1 is a degenerative disease, which is traditionally treated using insuline injections. These injections replace the missing hormone, but the complications can be far-reaching. Hyperglycemia is a common contributor to a number of complications like:

* Heart and vascular diseases
* Eye and kidney complaints
* Poor vascularization
* Damage to nerve cells (neuropathy)
* Diabetic feet
* High susceptibility for infections
* Erectile penile dysfunction

The GIOSTAR- Diabetes Mellitus treatment
Our innovative adult stem cell therapy with autologous stem cells (originating from your own body and being reimplanted) is unique and fights type 1 and type 2 diabetes at its roots, reducing hyperglycemia and consequently the abovementioned complications.

Stem cell treatment of Lupus

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder. SLE may affect the skin, joints, kidneys, and other organs. SLE (lupus) is an autoimmune disease. This means there is a problem with the body's normal immune system response. Normally, the immune system helps protect the body from harmful substances. But in patients with an autoimmune disease, the immune system cannot tell the difference between harmful substances and healthy ones. The result is an overactive immune response that attacks otherwise healthy cells and tissue. This leads to long-term (chronic) inflammation. GIOSAR scientists have ability to treat this disease using adult stem cell transplant.

Stem cell treatment of Myasthenia Gravis

Myasthenia gravis is an autoimmune neuromuscular disease leading to fluctuating muscle weakness and fatiguability. It is an autoimmune disorder, in which weakness is caused by circulating antibodies that block acetylcholine receptors at the post-synaptic neuromuscular junction inhibiting the stimulative effect of the neurotransmitter acetylcholine.

The hallmark of myasthenia gravis is fatigability. Muscles become progressively weaker during periods of activity and improve after periods of rest. Muscles that control eye and eyelid movement, facial expressions, chewing talking and swallowing are especially susceptible. The muscles that control breathing and neck and limb movements can also be affected. Often the physical examination yields results within normal limits. The onset of the disorder can be sudden. Often symptoms are intermittent. The diagnosis of myasthenia gravis may be delayed if the symptoms are subtle or variable.

To treat the disease, Giostar clinician first destroys the patients own immune cells with chemotherapy, then gives them purified blood forming stem cells. The modified stem cells then build new bone marrow, thus restoring the correct signaling pattern to the immune system and the immune system now has cells that do not attack the body.

Stem cell treatment of Cancer

Cancer (medical term: malignant neoplasm) is a class of diseases in which a group of cells display uncontrolled growth (division beyond the normal limits), invasion (intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread to other locations in the body via lymph or blood). These three malignant properties of cancers differentiate them from benign tumors, which are self-limited, and do not invade or metastasize. Most cancers form a tumor but some, like leukemia, do not. The branch of medicine concerned with the study, diagnosis, treatment, and prevention of cancer is oncology.

Cancer may affect people at all ages, even fetuses, but the risk for most varieties increases with age. Cancer causes about 13% of all human deaths. GISOTAR team of scientist has the ability to replace the cancer cells with the normal cells using stem cell based therapy.

Stem cell treatment of Cardiovascular Disease

The term cardiovascular disease technically refers to any disease affecting the cardiovascular system, but is usually used to refer to atherosclerosis, a specific form of arteriosclerosis.

As atherosclerosis has generally been advancing for a long time before the first symptoms emerge, most patients diagnosed with heart problems already suffer from well progressed atherosclerosis.

Stem cell treatment of Diabetes type 2

Type 2 diabetes used to be known as maturity onset, or non-insulin dependent diabetes. Although type 2 diabetes typically affects individuals over the age of 40, today it occurs at an increasingly younger age, especially in people who have a family history of diabetes.

Diabetes mellitus type 2 is by far the most common form, affecting 85 - 90% of all people with diabetes. Experts estimate that nearly one-third of people who have type 2 diabetes don't even know it. If the condition is left uncontrolled, the consequences (like with diabetes type 1) can be life threatening.

Hyperglycemia is a common contributor to a number of complications like:

* Heart and vascular diseases
* Eye and kidney complaints
* Poor vascularization
* Damage to nerve cells (neuropathy)
* Diabetic feet
* High susceptibility for infections
* Erectile penile dysfunction

Director of Business Development – West Bengal Region, India

Mr. Upadhyay is an entrepreneurial personality. After graduating in business and commerce, Mr. Upadhyay opted to found his own company. He started his own company i.e. SS Udyog, and the company has been very successful which has many branches in different parts of West Bengal, Orissa, Jharkhand, and UP. He is also a director of SS Popcorn Pvt Ltd, which deals with food and cosmetic products. He has been actively involved in trading with great success for last fifteen years and has gathered vast experience in the field.

ADDRESS:- 16, J.B.ROAD GHUSURI HOWRAH (W.B)- 711107

PHONE:- +91-9903069375,
033-2655-9882,

E-MAIL : santosh@gisotar.com
ssudyog_fr_u@yahoo.com
nil_fr_u@yahoo.com

Advisory Board Member – West Bengal Region, India

Prof. Sanyal is a very enthusiastic and extremely responsible member of the society. In addition to being a very learned person, who is actively practicing member of the Kolkata High Court Bar Council, he is also handling a number of responsibilities as chief or advisor of administrative bodies of different organizations. Names of a few organization is as listed below:

President, Howrah Chamber of Commerce & Industry (HCCI);

Management & Industrial Consultant, Legal Advisor of a number of Reputed Business Houses and Industries of West Bengal

Managing Director, Bengal HCCI Infrastructure Ltd., a Joint Venture Company with West Bengal Small Industries Development Corporation (WBSIDC), Government of West Bengal.

Member, Governing Body, Society for Modern Mini Tool Room and Training Center, Govt. of West Bengal.

Member, West Bengal Khadi & Village Industries Board under the aegis of Micro & Small Scale Enterprises and Textile Department, Govt. of West Bengal.

Chairman, Council of Consumer Guidance Centers, West Bengal, promoting consumer awareness against unfair trade practices.

Vice-President, Gandhi Smarak Nidhi, Bengal - a State branch of the Gandhi Smarak Nidhi, Rajghat, Delhi, a rural development institution on Gandhian model.

Vice-President, Self Help Group Promotional Forum, West Bengal promoted by CARE - India, a federal networking organization comprising of 22,000 Self Help Groups with 2,50,000 members.

Vice-President, Vidyashram - a pioneering Gandhian Organization of North Bengal with a history of over 60 years.

Vice-Chairman, Indian Institute of Public Administration (IIPA), Howrah Branch.

Member, Board of Management, Kasturba Gandhi National Memorial Trust, West Bengal Branch, West Bengal Gandhi Memorial Committee, Gandhi Vichar Parisad, which are national and state level Gandhian non-governmental organizations engaged in constructive & rural development work.

List of all organization helped by Prof Sanyal can be seen at his website.

WEBSITE:- www.sankarsanyal.com

E-MAIL:- sankar_sanyal@yahoo.co.in

×Close

is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. The point of using Lorem Ipsum is that it has a more-or-less normal distribution of letters, as opposed to using 'Content here,

is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. The point of using Lorem Ipsum is that it has a more-or-less normal distribution of letters, as opposed to using 'Content here,

Global Institute of Stem Cell Therapy and Research

Global Institute of Stem Cell Therapy and Research (GIOSTAR), headquartered in San Diego, California (U.S.A.), was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world.

We are the leaders in developing cutting edge stem cell based technology, supported by leading scientists with the pioneering publications in the area of stem cell biology. Our primary focus is to discover and develop a cure for human diseases with innovative and unique stem cell based therapies and products. Regenerative medicine promises treatment for those diseases previously regarded as incurable. GIOSTAR's ultimate aim is to maintain its leadership in the field of stem cell science and to continue developing affordable stem cell based therapy for those in need.

In July 2011, GIOSTAR inaugurated the world's first dedicated stem cell treatment hospital at Ahmedabad, Gujarat, India. This is a 125-bed state of the art facility with the most advanced on-site stem cell laboratory.
GIOSTAR STEM CELL HOSPITALS WORLDWIDE
Ahmedabad Hospital Varanasi Hospital China Hospital

What you knew about hospital is about to change
The GIOSTAR-SAVIOUR HOSPITAL is one of its kinds. It was designed by a team of hospital leaders, scientist, physicians, nurses and sta to promote the highest quality patient care.

A Place Dedicated to Healing
The facility's architectural design brings the outside world in through large sunlit windowslocated throughout the building. Soft, warm colours and artwork provide a comfortable, healingenvironment for patients and guests. The effective use of colour is also incorporated in the surgical suites, creating a calming effect for patients prior to stem cell transplant.

Tomorrow's hospital today
This is a multi-specialty high-tech tertiary care hospital with nine foors to accommodate 125 patients.• Six technologically advanced modular operation theatres, emergency operation theatre, 50 private intensive care units (ICU) +intensive critical care units (ICCU), CT SCAN and consulting rooms with modern facilities and technology.• Aesthetically designed in-patient and outpatient care facilities, focusing on the comfort & safety of patients and their families.• Centralized air conditioning system with unique periodical "Fresh Air Push" by additional duct system inall areas of the building to prevent infection.• PNEUMATIC TRANSFER SYSTEM for instant and automated transport of medicines and essential goods to operation theatres and to dierent location in the building.• Six units for renal dialysis at par with international standards • For critical instant care, ICCU's with 24-hour monitoring by MD physicians and intensivists.

Each Room is a Private RoomThis is the first hospital in Ahmebdabad that provides private rooms for all patients. Every roomsis designed for maximum care and encourages family participation, an important element incomforting patients and speeding their healing process. Quiet and peaceful, rooms offer acomfortable sofa/bed for guest to relax and spend the night. Caregivers are equipped with aneasy access tools for immediate response. A private bathroom in reach to the bed location reduces fall risk.

Families and Guests Welcome
A comfortable Family Lounge offers a relaxing atmosphere for guests.Amenities include concierge service, beverages and other nourishment. Free wireless Internet throughout thehospital enables guests to easily connect with others. A family resource centre provides health informationtailored to the needs of patients. Dedicated consultation rooms allow for private meetings among physicians, caregivers and family members.

Fine Dining ExperienceFocused on providing a fine dining experience, our cafeteria nestled on the ground floor offers a wide variety of wholesome dishes to cater to the overall well being of patrons.
GIOSTAR-SAVIOUR HOSPITAL
Near Bharat Petrol Pump, Near Lakhudi Talav,
Stadium Road, Navrangpura, Ahmedabad – 380014, Gujarat, INDIA
Madhya Pradesh Surat Hospital Chhattisgarh

GIOSTAR signed MOU with Government of Madhya Pradesh, India to develop the stem cell transplant program for the State of Madhya Pradesh.

Global Institute of Stem Cell Therapy and Research (GIOSTAR), Sis located in San Diego, California, U.S.A. We are pleased to announce that the investor summit held in November 2012 at Indore, MOU was entered between GIOSTAR and Government of Madhya Pradesh. The MOU was signed to treat the large, poor population in the State of Madhya Pradesh (India) suffering from the devastating disease of Sickle Cell Anemia for generations. It is believed that this disease spread via the travel routes of the Alexander the Great and his army.

As envisioned by Hon'ble Chief Minister of Madhya Pradesh, India, Shri Shivraj Singh Chauhan and stronglysupported by the Ministry of Health, the futuristic stem cell treatment provided by GIOSTAR will free the less fortunatepopulous suffering from Sickle Cell Anemia. Government of Madhya Pradesh in collaboration GIOSTAR has plans to build an advanced 200 bed stem cell treatment hospital in Indore. Thehospital will provide treatment for several other ailments usingGIOSTAR's stem cell technology.

IOSTAR aims to provide world-class medical expertise to develop the entire sickle cell stem cell transplant program for the state and also to train a local team of doctors to use advanced technology of stem cells to treat the sickle cell anemia many other diseases.

About us Vision, Mission and Values Management Advisory Board West Bengal, India

About us
GIOSTAR has an ability to treat several devastating Immunological diseases and Blood related diseases. These include Diabetes Type I, Lupus, Multiple Sclerosis, Crohns, Vasculitis, Scleroderma, Myasthenia Gravis, Sickle cell anemia, Leukemia, Lymphoma, Thalassemia and developing the therapies for Alzheimer's, Autism, Anti-Aging Treatments, Parkinson's, , Cancer, Heart and Retinal Degeneration, Amyyotrophic Lateral Sclerosis, Neuropathy, Osteoarthritis, Paralysis, Strokes, Spinal Cord Injuries, Skin Burns and Spinal Muscular Atrophy (SMA).

GIOSTAR is in process of opening dedicated stem cell treatment hospitals in Asia, Middle East, Africa, North and South America and Europe. The proposed facilities will be developed with the international support from public and private sectors grants and investments to provide stem cell based therapy for those suffering from degenerative or genetic diseases.

GIOSTAR uses autologous and allogeneic adult stem cells transplant to treat patients, following the highest medical standards.

GIOSTAR is leading the most advanced research to use embryonic stem (ES) cells and Induced Pluripotent Stem (IPS) cells to develop new therapies for clinical use.

GIOSTAR is a coalition of esteemed and illustrious scientific minds in the field of genetic and stem cell science. For over 15 years GIOSTAR team of scientists and clinicians have been involved in the development and utilization of stem cell based clinical protocols related to stem cell transplants.

The GIOSTAR team includes international leaders in the field of embryonic stem (ES) cells and Induced Pluripotent Stem (IPS) cells research and technologies. GIOSTAR team is the first in demonstrating the significance of ES cell use for the development of therapies for several degenerative diseases related to tissue and organs. The publications of these therapies have been thoroughly investigated and documented by many noted journals of medicine. GIOSTAR cutting-edge Stem Cell science will be used to treat qualified patients on needed basis.

GIOSTAR is using three kinds of stem cells : adult stem cell, human embryonic stem cell and Induced Pluripotent cells. The adult stem cell technology is well developed and being used regularly in clinical practice. Our clinicians are licensed to treat the patients using autologous (their own) and allogeneic (from others) adult stem cells for certain diseases. We are the leading private organization, which has state of art excellence in extraction of stem cell from a human body and use it for therapy. Our clinicians are treating the patients regularly using adult stem cells since 2000. GIOSTAR is leading the most advanced research to use embryonic stem (ES) cells and Induced Pluripotent Stem (IPS) cells to develop new therapies for clinical use.
Overview Of Stem Treatment Diseases Treated By Stem Cell Therapy

Overview Of Stem Treatment

Information on this webpage has been carefully compiled to give insight and important facts regarding the significance of stem cell therapies. This information will help the patient evaluate specific treatment options for their ailments.

Though stem cell therapy is the most promising therapy for several devastating degenerative diseases, scientists are still under the process of understanding the several unanswered questions related to stem cells. Recent advances in stem cell science indicate that stem cell therapies have strong promise in curing various diseases. However, there are no guarantees of a 100% success rate of any therapy including stem cell therapy. With every passing day, encouraging reports validate the increasing rate of success for stem cell therapy in helping more and more people cure their ailments. GIOSTAR offers different stem cell therapies while current medical treatments do not give satisfactory results to the patient.

GIOSTAR's medical team evaluates each prospective patient's medical history to determine the eligibility for specific stem cell treatment. Patients planning to undergo stem cell therapy are required to apply for a detailed consultation.

Types of Stem Cell used by GIOSTAR to treat diseases

Autologous
Stem cell collected from Bone marrow or from Peripheral stem cell

Autologous transplant means that the transplanted stem cell is derived from the person for whom the transplant is intended. In other words, the patient donates stem cells to himself. Giostar takes advantage of this technique and developed its proprietary techniques to deliver stem cell to patients to treat several autoimmune and blood related diseases.

Allogeneic
Stem cell collected from Bone marrow or from Peripheral stem cell

An allogeneic transplant requires a donor, usually a sibling. The immune system uses certain determinants to identfy things as self (autologous) or non-self (allogeneic). These determinants, also known as the HLA-system, will reject allogeneic tissue. Thus, tissue donors must be HLA-matched to the recipient in order for a successful transplant to take place. Furthermore, the recipient must be immunosuppressed to reduce the possibility of donor tissue (graft) rejection. Therefore, an allogeneic transplant is more complicated than an autologous transplant. Giostar highly accomplished clinicians have the ability to use the allogeneic transplant with the great success and uses this technique where autologous stem cells transplant does not work.

Stem Cells form peripheral blood

To treat the diseases, Giostar collect the stem cells simpler way using peripheral blood stream. In patients, for whom bone marrow harvesting is impossible for some reason or another, Giostar uses its highly advanced techniques and collect the stem cell form circulating peripheral blood and able to harvest and store over a several days to weeks by a techniques known as leukopheresis and cryopreservation respectively.

Peripheral blood stem cells accomplish this task much quicker. This accelerated blood cell recovery allows for a lower risk of infection and fewer transfusions compared to bone marrow stem cells. As a result, peripheral stem cell transplants in both the autologous and allogeneic transplant are much advance and Giostar Scientist and clinicians are pioneer in using this method to treat the patients.

Placental umbilical cord stem cells
Giostar uses cord blood stem cells deepening on the requirement of the treatment. The volume of blood and the total number of stem cells are generally small, but adults can reconstitute hematopoiesis with cord blood cells. Cord blood stem cells are immunologically naïve and therefore perfect HLA-matching is not required. More important are the number of stem cells and the volume of infused blood. Furthermore, large cord blood banks have made cord blood cells rapidly available providing an advantage compared to volunteer donor stem cells.

Mesenchymal stem cells
Mesenchymal stem cells, or MSCs, are multipotent stem cells that can differentiate into a variety of cell types, including: osteoblasts (bone cells), chondrocytes (cartilage cells), adipocytes (fat cells), and beta-cell to produce insulin. Giostar Scientists has ability to collect, store, differentiate and use these cells to treat several degenerative diseases, where peripheral and bone marrow cells do not work.

Reviewing the condition of patients, Giostar scientists and clinicians decide the type of stem cell to be used for the treatment of a particular type of disease and patients.

Advanced Stem Cell treatment under development by Giostar Scientists

Human Embryonic Stem (ES) Cell
Embryonic stem cells, as their name suggests, are derived from embryos. Most embryonic stem cells are derived from embryos that develop from eggs that have been fertilized in vitro—in an in vitro fertilization clinic—and then donated for research or therapeutic purposes with informed consent of the donors. They are not derived from eggs fertilized in a woman's body. These cells have capacity to make any human organ cell. Giostar scientist has developed the method to differentiate these cells into specific types of cells such as blood, liver, heart, muscle, neural and skin cells and successfully tested to repair the damage organs in animals. Now Giostar is working to develop the method to repair the organs in humans using these cells. Giostar scientists have published their findings in the top rated peer review medical and research journals.

Induced pluripotent stem cells (iPSCs)

Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to an embryonic stem cell–like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells. Although these cells meet the defining criteria for pluripotent stem cells, it is not known if iPSCs and embryonic stem cells differ in clinically significant ways. Human iPSCs demonstrate important characteristics of pluripotent stem cells including expressing stem cell markers, from all three germ layers, and being able to contribute to many different tissues when injected into mouse embryos at a very early stage in development. Giostar scientists are in advanced stage to develop the treatment of several degenerative diseases using iPSCs.

GIOSTAR uses autologous and allogeneic adult stem cells transplant to treat patients at its worldwide state of the art stem cell facilities at the highest medical standards.
FAQ's
General Information

Q: Where does GIOSTAR treat the patients?
A: Currently we treat patients at Ahmedabad, Gujarat, India.Other Global Locations are under development.

Q: What is the cost of treatment?
A: The price varies depending upon the implantation method(s) employed as well as the type and stage of disease.

There may be additional charges for special cases such as those involving general anesthesia, multiple implantation methods or infected bone marrow samples (HIV, Hepatitis B or Hepatitis C).

Q: Dose the price include flights and hotel?
A: No.

Q: For how long does a patient need to say at the GIOSTAR facility?
A: The patient will be at the GIOSTAR facility for 1 to 2 weeks depending on his/her condition and the treatment.

Q: Do I need to be hospitalized?
A: No. Generally, stem cell collection and transplantation does not require hospitalization (except in some special cases)

Q: What is the primary language of communication at GIOSTAR?
A: While English is the primary language of communication, GIOSTAR's employees speak several international languages as well. If required, we can organize native speakers and translators.

Q: How does stem cells therapy work?
A: Stem cells have the ability to repair and regenerate damaged tissues by replacing damaged cells. Stem cell therapy uses this function by administering these cells systematically and in high concentrations directly into the damaged tissue, where they advance the self-healing process. The procedure that lies behind this mechanism is largely unknown, but research suggests that stem cells discharge certain substances that activate the diseased tissue. It is also believed that single damaged somatic cells (e.g. single neurocytes in the spinal cord or endothelium cells in vessels) are replaced by stem cells. Most scientists agree that stem cell research has tremendous life-saving potential and could revolutionize the study and treatment of diseases and injuries.

Q: Are there any ethical concerns surrounding adult stem cell research and therapy?
A: There are no ethical issues involved in adult stem cell treatments. At this point we do not use embryonic stem cells; these underwent some ethical and moral debate.

Bone Marrow Collection (BMC)

Q: What is bone marrow and how are stem cells collected from it?
A: Bone marrow is a specific tissue found inside the hollow part of bones. Its main purpose is to produce stem cells that give rise to the various blood cell types, especially white blood cells, red blood cells and platelets. Each stem cell can multiply into millions of daughter stem cells. Most stem cells are found in the bone marrow of the chest, hips, skull, upper arms and legs. If the stem cells develop into fully functional cells, they are released into the blood. A smaller number of undifferentiated stem cells are also found in the bloodstream.

Q: How is bone marrow donation carried out?
A: Around150 ml of bone marrow is collected from the hipbone using a thin needle under local anaesthesia.

Q: Is the bone marrow collection procedure painful?
A: You will experience the pain equivalent of a needle injection but nothing more severe.

Q: How much time does bone marrow collection take?
A: Bone marrow collection takes about 30 - 60 minutes.

Stem Cell Transplant

Q: How many stem cells get transplanted?
A: This depends on the patient's condition and the type of disease.

Q: What can one do if a person does not have adequate stem cells?
A: This is a rare situation. In the rare case that your sample does not contain enough stem cells, it might be possible to do another bone marrow or peripheral blood collection. There will be an additional cost for any additional bone marrow or peripheral blood collection. Our clinicians will discuss this option with you if another collection is deemed necessary and plan accordingly.

Q: What is the process of stem cell transplantation?
A: It varies from patient to patient and depends on the diseases at hand. GIOSTAR generally uses the following methods to administer stem cells:

• Intravenous administration
• Administration via a catheter using angiography
• Direct injection into the target area by way of surgery
• Retrobulbar Injection
• Direct injection in the affected area such as a knee joint

Q: Are there any risks related to adult stem cell therapy?
A: In general, autologous (i.e. from the patient's own cells) stem cell therapy does not cause adverse effects. However, all surgical procedures have few risks related to anaesthesia, infections, temporary discomfort, bleeding or wound healing problems. The benefits and possible side effects vary from one disease to the next and between individuals. This should be discussed in detail with the transplant specialist involved in your case.

Q: Some reports state that injected stem cells may develop into tumours. Is this true?
A: Some reports indicate that stem cells not only support the regeneration of diseased tissues but may also increase tumour cells. This risk is greater with embryonic stem cells compared to adult stem cells, especially if the embryonic stem cells are injected without prior differentiation. Animal testing has not yet found any cancer-causing potential in adult stem cells.

Medical Evaluation

Q: How does GIOSTAR evaluate for treatment?
A: Step 1: Please contact us with details about your condition at contact@giostar.com

Step 2: Subsequently, the GIOSTAR medical board will review your information. This normally takes 3-5 business days. Once this process is completed, a patient consultant will contact you regarding the next steps.

Treatment Scheduling
Q: What is a typical treatment schedule?
A: Typically, stem cell are collected through the patient's bone marrow or peripheral blood during the working days. The transplantation procedure will be scheduled in the same week.

Travel Information
Q: Does GIOSTAR help patients with travel?
A: GIOSTAR offers various kinds of travel assistance through its travel agents.

Q: Does GIOSTAR offer assistance in bringing patients from airport to hospital facility?
A: GIOSTAR provides ambulances and car services for a modest charge. This service is offered to and from airports.

Payment
Q: What is the accepted method of payment for getting this treatment?
A: GIOSTAR requires the entire payment to be received, the day the patient is admitted to our facility. Payment can be made using a credit card, traveller's checks, international bank drafts or wire transfers.

Worldwide Stem Cell Hospitals & Research Facilities

U.S.A. | San Diego Current Research Facility

India | Ahmedabad - New State of the Art Hospital Now Open
Surat - Sickle Cell Anemia Stem Cell Transplant Program - GOVT MEDICAL COLLEGE
and CIVIL HOSPITAL. In association with Government of Gujarat,India

U.A.E. | Dubai - New State-of-the Art Hospital & Research Facility by 2014

Brazil | Rio De Janeiro - New-State-of the Art Hospital & Research Facility by 2014

Thailand | Bangkok - New State-of-the Art Hospital & Research Facility by 2014

China | Hong Kong - New State-of-the Art Hospital & Research Facility by 2014

England | London - New State-of-the Art Hospital & Research Facility by 2014

Publications By Scientists

1. Embryonic Stem Cells in Medicinal Chemistry and Drug Development.
Srivastava AS.
Curr Top Med Chem. 2011 Mar 30.

2. Artificial Hematopoietic Stem Cell Niche: Bioscaffolds to Microfluidics to Mathematical Simulations.
Didwania M, Didwania A, Mehta G, Basak GW, Yasukawa S, Takayama S, de Necochea-Campion R, Srivastava A, Carrier E.
Curr Top Med Chem. 2011 Mar 30.

3. Cancer Stem Cells and Colorectal Cancer: An Overview.
Dhawan P, Ahmad R, Srivastava AS, Singh AB.
Curr Top Med Chem. 2011 Mar 30.

4. Mitochondrial function controls proliferation and early differentiation potential of embryonic stem cells.
Mandal S, Lindgren AG, Srivastava AS, Clark AT, Banerjee U.
Stem Cells. 2011 Mar;29(3):486-95.

5. Singh, U.P., Narendra P. Singh, Balwan Singh, Lorne J. Hofseth, Robert L Price, Mitzi Nagarkatti, and Prakash S. Nagarkatti.
(2011) Role of resveratrol-induced CD11b+ Gr-1+ myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3+ T cells and amelioration of chronic colitis in IL-10-/- mice. (Accepted in Brain, Behavior and Immunity).

6. Singh, U.P.*, Narendra P. Singh*, Balwan Singh, Robert L Price, Mitzi Nagarkatti,and Prakash S. Nagarkatti.
(2011) Activation of Aryl Hydrocarbon Receptor Leads to Reciprocal Epigenetic Regulation of FoxP3 and IL-17 genes and Amelioration of Experimental Colitis. (Accepted in PLoS ONE).

7. Singh, U.P., Narendra P. Singh, Balwan Singh, Lorne J. Hofseth, Robert L Price,Mitzi Nagarkatti, and Prakash S. Nagarkatti (2010) Resveratrol (trans-3, 5, 4'- trihydroxystilbene) induces SIRT1 and down-regulates NF-kB activation toabrogate DSS-induced colitis. J. Pharmacology & Exp. Therapeutics. 332(3): 829-839.

8. Xiangli Cui, Yu Jin, Anne B. Hofseth, Alexander Chumanevich, Mitzi Nagarkatti,Prakash S. Nagarkatti, Udai P. Singh, and Lorne J. Hofseth (2010) Resveratrolsuppresses colitis and colon cancer associated with colitis. Cancer-Prevention Research. 3(4): 549-559.

9.Singh, U.P., Narendra P. Singh, Balwan Singh, Mishra Manoj, Mitzi Nagarkatti, Prakash S. Nagarkatti and Singh SR (2010) Stem cells as potential therapeutic targets for Inflammatory Bowel Disease. Frontiers in Biosciences S (2): 993-1008.

10. Lorne J. Hofseth, Singh, U.P., Narendra P. Singh, Mitzi Nagarkatti, and Prakash S. Nagarkatti (2010) Taming the beast within: resveratrol suppresses colitis and prevents colon cancer. Aging 2(4): 183-184.

11.Yu Jin, Xiangli Cui, Udai P. Singh, Brook Harmon, Philip Cavicchia, Anne B. Hofseth, Venkata Kotakadi, Brandy Stroud, Alexander A. Chumanevich,James R. Hebert, Thomas G. Hurley, and Lorne J. Hofseth (2010) Systemic inflammatory load in humans is suppressed by consumption of two formulations of dried, encapsulated juice concentrate. Molecular Nutrition and Food Research (54): 1-9.

12. Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia.
Jung AS, Holman PR, Castro JE, Carrier EK, Bashey A, Lane TA, Nelson CL, Pu M, Messer K, Corringham SM, Ball ED.
Biol Blood Marrow Transplant. 2009 Oct;15(10):1306-13. Epub 2009 Aug 3.

13.Human embryonic stem cells hemangioblast express HLA-antigens.
Basak GW, Yasukawa S, Alfaro A, Halligan S, Srivastava AS, Min WP, Minev B, Carrier E.
J Transl Med. 2009 Apr 22;7:27.

14. Multiple myeloma bone marrow niche.
Basak GW, Srivastava AS, Malhotra R, Carrier E.
Curr Pharm Biotechnol. 2009 Apr;10(3):345-6. Review.

15.CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED.
Blood. 2009 Feb 12;113(7):1581-8. Epub 2008 Oct 30.

16. Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies.
D'Orlans-Juste P, Houde M, Rae GA, Bkaily G, Carrier E, Simard E.
Vascul Pharmacol. 2008 Aug-Sep;49(2-3):51-62. Epub 2008 Jul 12. Review.

17. Singh U.P., Singh, R., Singh, S., Karls R.K., Quinn F.D., Taub, D.D., and J.W. Lillard, Jr. (2008) CXCL10+ T cells and NK cells assist in the recruitment and activation of CXCR3+ and CXCL11+ leukocytes during Mycobacteria-enhanced colitis. BMC Immunol. 9(1): 25.

18. Singh U.P.*, Sakthivel, S.K.*, Singh, S., Taub, D.D., Igietseme, J.U., and J.W. Lillard, Jr. (2008) CCL5 regulation of mucosal chlamydial immunity and infection. BMC Microbiol. 8:136.

19. Singh U.P.*, Sakthivel, S.K.*, Singh, S., Taub, D.D., Kristian R Novakovic, and J.W. Lillard, Jr. (2008) CXCL10-blockade protects mice from cyclophosphamide- induced cystitis. J immune Based Ther Vaccines. 6(1): 6.

20. Singh U.P., Singh, S., Singh, R., Cong, Y., Taub, D.D. and J.W. Lillard, Jr. (2008) Chronic colitis and CXCL10-producing mucosal T helper, NK and NKT cells in IL10-/- mice can be abrogated by CXCL10 blockade. Journal of Interferon and Cytokine Research. 28(1): 31-43.

21. Singh U.P., A. Krishna, and Kunwar P. Bhatnagar (2008) Changes in serum leptin, insulin, androstenedione, and luteinizing hormone during ovarian cycle in the bat, Taphozous longimanus. Acta Biologica Hungarica. 59(1): 1-16.* Indicate equal contribution

22. Prospects of embryonic stem cells in treatment of hematopoietic disorders.
Srivastava AS, Malhotra R, Esmaeli-Azad B, Lane T, Carrier E.
Curr Pharm Biotechnol. 2007 Oct;8(5):305-17. Review.

23. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A, Donohue M, Liu L, Medina B, Corringham S, Ihasz A, Carrier E, Castro JE, Holman PR, Xu R, Law P, Ball ED, Lane TA.
Transfusion. 2007 Nov;47(11):2153-60.

24. Ovarian recovery after stem cell transplantation.
Liu J, Malhotra R, Voltarelli J, Stracieri AB, Oliveira L, Simoes BP, Ball ED, Carrier E.
Bone Marrow Transplant. 2008 Feb;41(3):275-8. Epub 2007 Oct 22.

25. Embryonic stem cells ameliorate piroxicam-induced colitis in IL10-/- KO mice.
Srivastava AS, Feng Z, Mishra R, Malhotra R, Kim HS, Carrier E.
Biochem Biophys Res Commun. 2007 Oct 5;361(4):953-9. Epub 2007 Aug 1.

26. Thrombopoietin enhances generation of CD34+ cells from human embryonic stem cells.
Srivastava AS, Nedelcu E, Esmaeli-Azad B, Mishra R, Carrier E.
Stem Cells. 2007 Jun;25(6):1456-61. Epub 2007 Mar 22.

27. Singh U.P., Singh S, Chandrasekar Venkataraman and James W. Lillard, Jr. (2007) CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication. Endocrine, Metabolic & Immune Disorder: Drug Target. 7(2): 111- 123.

28. Singh U.P., Singh S, Singh R, Frederick D. Quinn, Morris E. Potter & James W. Lillard, Jr. (2007) Influence of Mycobacterium avium paratuberculosis on colitis development and specifics immune responses during disease. Infection and Immunity. 75 (8): 3722-3278.

29. Dexamethasone facilitates erythropoiesis in murine embryonic stem cells differentiating into hematopoietic cells in vitro.
Srivastava AS, Kaushal S, Mishra R, Lane TA, Carrier E.
Biochem Biophys Res Commun. 2006 Jul 28;346(2):508-16. Epub 2006 Jun 2.

30. Transplanted embryonic stem cells successfully survive, proliferate, and migrate to damaged regions of the mouse brain.
Srivastava AS, Shenouda S, Mishra R, Carrier E.
Stem Cells. 2006 Jul;24(7):1689-94. Epub 2006 Mar 30.

31. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older.
Bashey A, Liu L, Ihasz A, Medina B, Corringham S, Keese K, Carrier E, Castro JE, Holman P, Lane TA, Hassidim K, Ball ED.
Leuk Res. 2006 Apr;30(4):503-6. Epub 2005 Nov 21.

32. Improving the efficiency of PBPC collection by pre-apheresis peripheral blood and mid-apheresis product measurements of CD34 cells.
Lane TA, Bashey A, Carrier E, Holman P, Castro J, Mullen M, Ward DM, Ada O, Ball ED.
Cytotherapy. 2004;6(4):318-27.

33. In utero DNA immunisation. Immunity over tolerance in fetal life.
Rizzi M, Gerloni M, Srivastava AS, Wheeler MC, Schuler K, Carrier E, Zanetti M.
Vaccine. 2005 Jul 21;23(33):4273-82.

34. Hematopoietic stem cell transplantation for multiple sclerosis.
Burt RK, Cohen B, Rose J, Petersen F, Oyama Y, Stefoski D, Katsamakis G, Carrier E, Kozak T, Muraro PA, Martin R, Hintzen R, Slavin S, Karussis D, Haggiag S, Voltarelli JC, Ellison GW, Jovanovic B, Popat U, McGuirk J, Statkute L, Verda L, Haas J, Arnold R.
Arch Neurol. 2005 Jun;62(6):860-4. Review.

35. In utero gene therapy: prospect and future.
Chauhan DP, Srivastava AS, Moustafa ME, Shenouda S, Carrier E.
Curr Pharm Des. 2004;10(29):3663-72. Review.

36. Chimerism and tolerance post-in utero transplantation with embryonic stem cells.
Moustafa ME, Srivastava AS, Nedelcu E, Donahue J, Gueorguieva I, Shenouda SS, Minev B, Carrier E.
Transplantation. 2004 Nov 15;78(9):1274-82.

37. T-cell depletion improves outcome after autologous stem cell transplant in patients with systemic lupus erythematosus (SLE).
Kamrava MR, Anderson EM, Kalunian K, Bashey A, Holman P, Medina B, Ball ED, Carrier E.
Bone Marrow Transplant. 2005 Jan;35(2):205-6. No abstract available. Erratum in: Bone Marrow Transplant. 2005 Feb;35(3):321.

38. A regulatory role of Wnt signaling pathway in the hematopoietic differentiation of murine embryonic stem cells.
Feng Z, Srivastava AS, Mishra R, Carrier E.
Biochem Biophys Res Commun. 2004 Nov 26;324(4):1333-9.

39. In utero detection of T7 phage after systemic administration to pregnant mice.
Srivastava AS, Chauhan DP, Carrier E.
Biotechniques. 2004 Jul;37(1):81-3.

40. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, Carrier E.
Bone Marrow Transplant. 2004 Oct;34(7):581-7.

41. Induction of apoptosis in human lung cancer cells by curcumin.
Radhakrishna Pillai G, Srivastava AS, Hassanein TI, Chauhan DP, Carrier E.
Cancer Lett. 2004 May 28;208(2):163-70.

42. Purification and properties of cytosolic alanine aminotransferase from the liver of two freshwater fish, Clarias batrachus and Labeo rohita.
Srivastava AS, Oohara I, Suzuki T, Shenouda S, Singh SN, Chauhan DP, Carrier E.
Comp Biochem Physiol B Biochem Mol Biol. 2004 Feb;137(2):197-207.

43. Immunological factors that affect the in vivo fate of T7 phage in the mouse.
Srivastava AS, Kaido T, Carrier E.
J Virol Methods. 2004 Jan;115(1):99-104.

44. Singh U.P., S. Singh, R. Palaniappan, D.D. Taub, and J.W. Lillard, Jr. (2004) vMIP-II versus I-309 effects on adaptive immunity. Journal of Immunology 173:5509-5516.

45. Singh U.P., Singh S., Boyaka, P.N., McGhee, J.R., and Lillard, J.R. (2004) Granulocyte chemotactic protein-2 mediates adaptive immunity through CXCR1 interactions and CD28/B7 upregulation. Journal of Leukocyte Biology. 76:1240- 1247.

46. FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia.
Tanner ML, Hoh CK, Bashey A, Holman P, Sun C, Broome HE, Lane T, Ball ED, Carrier E.
Bone Marrow Transplant. 2003 Sep;32(6):581-5.

47. Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus.
Burt RK, Marmont A, Arnold R, Heipe F, Firestein GS, Carrier E, Hahn B, Barr W, Oyama Y, Snowden J, Kalunian K, Traynor A.
Bone Marrow Transplant. 2003 Aug;32 Suppl 1:S49-51.

48. Tolerance and immunity following in utero transplantation of allogeneic fetal liver cells: the cytokine shift.
Sefrioui H, Donahue J, Gilpin EA, Srivastava AS, Carrier E.
Cell Transplant. 2003;12(1):75-82.

49.Lillard, Jr., J. W., U.P. Singh, P.N. Boyaka, S. Singh, D.D. Taub and J.R. McGhee (2003) MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood.101: 807-814.

50. Singh U.P., S. Singh, D.D. Taub, and J.W. Lillard, Jr. (2003) Inhibition of IP-10 abrogates colitis in IL-10-/- mice. Journal of Immunology.171: 1401-1406.

51. Singh U.P., S. Singh, D.D. Taub, and J.W. Lillard, Jr. (2003) Interferon-inducible chemokines differentially mediate adaptive immunity and colitis. Journal of Interferon & Cytokine Research.23(10): 591-600.

52. Alloreactivity following in utero transplantation of cytokine-stimulated hematopoietic stem cells: the role of recipient CD4(-) cells.
Sefrioui H, Donahue J, Srivastava AS, Gilpin E, Lee TH, Carrier E.
Exp Hematol. 2002 Jun;30(6):617-24.

53. Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation.
Bashey A, Corringham S, Gilpin E, Fields KK, Smilee RC, DeFrancisco C, Santos-Ada O, Holman P, Carrier E, Ho AD, Lane TA, Ball ED, Janssen WE, Law P.
Cytotherapy. 2000;2(3):195-200.

54. Murine Sca-1(+)/Lin(-) cells and human KG1a cells exhibit multiple pseudopod morphologies during migration.
Francis K, Palsson B, Donahue J, Fong S, Carrier E.
Exp Hematol. 2002 May;30(5):460-3.

55. Non-myeloablative transplants for congenital diseases.
Donahue J, Carrier E.
Cancer Treat Res. 2002;110:177-211. Review.

56. Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion.
Voltarelli JC, Ahmed H, Paton EJ, Stracieri AB, Holman P, Bashey A, Coutinho M, Simoes BP, Ball ED, Carrier E.
Bone Marrow Transplant. 2001 Jul;28(1):97-9.

57. Postnatal cytokines and boosts improve chimerism and hematological parameters in beta-thalassemic mice transplanted in utero.
Donahue J, Gilpin E, Young D, Carrier E.
Transplantation. 2001 May 27;71(10):1491-4.

58. Microchimerism does not induce tolerance and sustains immunity after in utero transplantation.
Donahue J, Gilpin E, Lee TH, Busch MP, Croft M, Carrier E.
Transplantation. 2001 Feb 15;71(3):359-68.

59. Microchimerism does not induce tolerance after in utero transplantation and may lead to the development of alloreactivity.
Carrier E, Gilpin E, Lee TH, Busch MP, Zanetti M.
J Lab Clin Med. 2000 Sep;136(3):224-35.

60. AB035673
Paralichthys olivaceus ppsb mRNA for pancreatic protein with two somatomedin B domains, complete cds
gi|6561906|dbj|AB035673.1|[6561906]

61. AB029757
Paralichthys olivaceus mRNA for elastase 3 precursor, complete cds
gi|6815046|dbj|AB029757.2|[6815046]

62. AB029752
Paralichthys olivaceus mRNA for trypsinogen 3, complete cds
gi|6815044|dbj|AB029752.2|[6815044]

63. AB029758
Paralichthys olivaceus mRNA for elastase 4 precursor, partial cds
gi|5441868|dbj|AB029758.1|[5441868]

64. AB029756
Paralichthys olivaceus mRNA for elastase 2 precursor, partial cds
gi|5441864|dbj|AB029756.1|[5441864]

65. AB029755
Paralichthys olivaceus mRNA for elastase 1 precursor, complete cds
gi|5441862|dbj|AB029755.1|[5441862]

66. AB029754
Paralichthys olivaceus mRNA for chymotrypsinogen 2, complete cds
gi|5441860|dbj|AB029754.1|[5441860]

67. AB029753
Paralichthys olivaceus mRNA for chymotrypsinogen 1, complete cds
gi|5441858|dbj|AB029753.1|[5441858]

68. AB029751
Paralichthys olivaceus mRNA for trypsinogen 2, partial cds
gi|5441854|dbj|AB029751.1|[5441854]

69. AB029750
Paralichthys olivaceus mRNA for trypsinogen 1, complete cds
gi|5441852|dbj|AB029750.1|[5441852]

70. AB196515
Paralichthys olivaceus COL1A3 mRNA for type 1 collagen alpha 3, partial cds
gi|56565284|dbj|AB196515.1|[56565284]

71 AB196514
Paralichthys olivaceus COL1A2 mRNA for type 1 collagen alpha 2, complete cds
gi|56565282|dbj|AB196514.1|[56565282]

72. AB196513
Paralichthys olivaceus COL1A1 mRNA for type 1 collagen alpha 1, complete cds
gi|56565280|dbj|AB196513.1|[56565280]

73. AB196517
Paralichthys olivaceus COL1A3 gene for type 1 collagen alpha 3, promoter region
gi|56565287|dbj|AB196517.1|[56565287]

74. AB196516
Paralichthys olivaceus COL1A1 gene for type 1 collagen alpha 1, promoter region
gi|56565286|dbj|AB196516.1|[56565286]

75. AB099302
Paralichthys olivaceus CPB mRNA for carboxypeptidase B, partial cds
gi|27529695|dbj|AB099302.1|[27529695]

76. AB099301
Paralichthys olivaceus CPA1 mRNA for carboxypeptidase A1, partial cds
gi|27529693|dbj|AB099301.1|[27529693]

77. AB099300
Paralichthys olivaceus CPA2 mRNA for carboxypeptidase A2, complete cds
gi|27529691|dbj|AB099300.1|[27529691]

78. AB049616
Paralichthys olivaceus mRNA for keratin, partial cds
gi|10716083|dbj|AB049616.1|[10716083]

79. AB037674
Paralichthys olivaceus VDRa mRNA for vitamin D receptor a, complete cds
gi|7670337|dbj|AB037674.1|[7670337]

80. AB037673
Paralichthys olivaceus VDRb mRNA for vitamin D receptor b, complete cds
gi|7670328|dbj|AB037673.1|[7670328]

81. Recruitment of engrafted donor cells postnatally into the blood with cytokines after in utero transplantation in mice.
Carrier E, Lee TH, Busch MP, Cowan MJ.
Transplantation. 1997 Aug 27;64(4):627-33.

81. The exicting life of Elisabeth Carrier, nurse without borders. Interview by Sylvie Vallieres.
Carrier E.
Infirm Que. 1997 Mar-Apr;4(4):38-9.

82. Induction of tolerance in nondefective mice after in utero transplantation of major histocompatibility complex-mismatched fetal hematopoietic stem cells.
Carrier E, Lee TH, Busch MP, Cowan MJ.
Blood. 1995 Dec 15;86(12):4681-90.

83. Glucocorticoid receptors in lymphocytes in anorexia nervosa.
Girardin E, Garoscio-Cholet M, Dechaud H, Lejeune H, Carrier E, Tourniaire J, Pugeat M.
Clin Endocrinol (Oxf). 1991 Jul;35(1):79-84.

84. Lymphomas presenting as histologically unclassified neoplasms: characteristics and response to treatment.
Horning SJ, Carrier EK, Rouse RV, Warnke RA, Michie SA.
J Clin Oncol. 1989 Sep;7(9):1281-7.

Giostar Philanthropic Projects

GIOSTAR FOUNDATION (INDIA) is the philanthropic wing of Global Institute of Stem Cell Therapy and Research (GIOSTAR), located at San Diego, California, U.S.A. We are pleased to announce that MOU was entered between GIOSTAR and Government of Gujarat, India in January 2009. GIOSTAR FOUNDATION's purpose is to treat the large, poor tribal populations in the southern part of State of Gujarat (India) suffering from the devastating disease of Sickle Cell Anemia for generations. It is believed that this disease spread via the travel routes of the Alexander the Great and his army.

As envisioned by Hon'ble Chief Minister of Gujarat, India, Shri Narendra Modi and strongly supported by the Gujarat Ministry of Health, the futuristic stem cell treatment provided by GIOSTAR will free the less fortunate tribal populous suffering from Sickle Cell Anemia. The Government has identified and assigned the Surat Civil Hospital to treat the tribal belt suffering from this ailment. The Government of Gujarat has also approved the funds and is in the process of building a state of the art stem cell lab and developing a stem cell treatment ward for patients (in Phase 1). In Phase 2, the Government has plans to build an advanced 50 to 100 bed stem cell treatment hospital in the Surat Civil Hospital Campus. The purpose of this is to treat several other ailments using GIOSTAR's stem cell technology.

GIOSTAR FOUNDATION aims to provide world-class medical expertise to develop the entire sickle cell treatment program and train.It also endeavours to train a local team of doctors to use our advanced technology of stem cells to treat the sickle cell anemia.

GIOSTAR'S Most Advanced Stem Cell Treatment Will Be
a Blessing For The Less Fortunate Tribal Populous

Individual Patients, Medical Institutions and Hospitals may use following form for further enquiries. You may also contact us at contact@giostar.com

Institutions interested in Clinical Trial Projects for certain diseases may also use following form for further enquiries.

Address:
4370 La Jolla Village Drive,P.O. Box 270575,
4th Floor, San Diego,San Diego, California 92198,
California 92122,U.S.A.U.S.A.

Inquiry:   * All fields are mandatory
Patient's Name: Patient's Age:
Email Id: Phone No:
City: State:
Country:    
How did you hear about us?  

Individuals and/or institutional investors may use following form for further enquiries. You may also contact us at info@giostar.com

Address:
4370 La Jolla Village Drive,P.O. Box 270575,
4th Floor, San Diego,San Diego, California 92198,
California 92122,U.S.A.U.S.A.

Inquiry:
* All fields are mandatory
Investor's Name:
Institution Name:
Email Id:
Phone No:
City:
State:
Country:
How did you hear about us?
Stemcell News GIOSTAR News